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ABSTRACT 
The present thesis describes the effect and timing of photochemotherapy in relation to the 
onset and severity of cutaneous graft-versus-host (GvHD) in relation to the survival and cure 
of patients. Leukemia is the most common childhood malignancy and an entity of cancer that 
is increasing in elderly. Allogeneic stem cell transplantation following myeloablative 
treatment (conditioning) and using methotrexate-based prophylaxis still remains the best 
choice to cure of high-risk acute and relapsed chronic myeloid leukemia. To improve the 
long-term disease free survival, we have to redirect the adoptive immunity from GvHD 
towards graft-versus-leukemia (GvL).  
The aim of the present thesis was to test the theory postulating that effects of 
photochemotherapy are confined to the skin. The theory was tested by whether 
photochemotherapy had effects on GvHD in liver and gastrointestinal tract (GI), and if it 
affects the anti-tumor immunity post transplantation. The complete response in GI and liver 
in addition to the pulmonary mortality after photochemotherapy, which intercalate with 
DNA, were compared in two groups of patients. One group had received myeloablative 
ionizing irradiation, which leaves long-lasting DNA-breaks and the second group who 
received myeloablative chemotherapy including busulfan, which alkylates DNA. The effect 
on anti-tumor immunity was determined by the effect on the cumulative GvL with regard to 
whether photochemotherapy was given direct after the onset of cutaneous acute-GvHD or 
after a week. 
The main theoretical background to the present studies was the effect of photochemotherapy 
on cell mediated immunity evident by an inhibition of the delayed type hypersensitivity of the 
skin and the ability to induce circulating immunomodulatory regulatory-T cells in human. 
Four different patient populations were investigated; patients with cutaneous acute-GvHD; 
patients with cutaneous- and visceral acute-GvHD; patients with acute leukemia; and patients 
with chronic myeloid leukemia. Complete response, tumor immunity (GvL) and survival 
were considered as outcomes. Established risk factors including transplantation across the 
female-male barrier were assessed. 
The key result was the possible synergistic-effect between ionizing irradiation and 
photochemotherapy, which may cure GI GvHD. Furthermore, our results indicated that 
cutaneous acute-GvHD may enhance the anti-tumor immunity, but also the pulmonary 
mortality. However, cutaneous complete response to photochemotherapy may decrease the 
pulmonary mortality after TBI. The studies of patients with acute-leukemia and chronic-
myeloid-leukemia implied that after transplantation, the adoptive tumor immunity was 
modulated by the timing of photochemotherapy with regards to the onset of cutaneous acute-
GvHD.  
In conclusion, photochemotherapy has effects on disease in internal organs. The overall 
results suggest that the optimal time to start the photochemotherapy in patients with 
hematological malignancy is at least after the first week of cutaneous acute-GvHD. 
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FoxP3 Forkhead box 3 
G1 Gap 1, Cell cycle checkpoint or cell cycle phase 
Gut Gastrointestinal tract 
GI Gastrointestinal tract 
G-CSF Granulocyte Colony Stimulating Factor 
Gp120 Envelope glycoprotein 120 
GvHD Graft-versus-host disease 
GvL Graft-versus-leukemia reaction 
cGy Centi-Gray 
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HGF Hepatocyte Growth Factor 
HHV6 Human Herpes Virus 6 
HIV Human Immunodeficiency Virus 
HLA Histocompatability Leukocyte Antigen (Human) 
HSV Herpes simplex virus 
HvGR Host-versus-graft reaction, a rejection of the transplanted graft 
HY Human minor histocompatibility antigen Y, bound to the Y chromosome 
IBMTR International Bone Marrow Transplant Register 
ICL Interstrand cross-link 
INH Isonicotinylhydrazide 
IL-(X) Interleukin-(X) 
IPS Interstitial pneumonia syndrome 
KIR Killer cell immunoglobuline receptor 
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MHC Major Histocompatability Complex 
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MRSA Multi Resistant Staphylococcus Aureus Type A 
mTOR Mammalian target of rapamycin 
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MUD Matched unrelated donor 
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PBSC Peripheral Blood Stem Cell 
PCT Pulmonary Cytolitic Trombi 
PERDS Peri-engraftment respiratory distress syndrome 
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PTLD Post-transplant lymphoproliferative disease  
PTE Pulmonary Tromboembolus 
PRICHE Predicted Indirectly ReCognizable Epitopes 
PVOD Pulmonary Veno-occlusive syndrome 
Rad Radiation absorbed dose (0.01 Gy) 
RIC Reduced intensity conditioning 
RSV Respiratory Syncytial Virus 
STROBE Strengthen the report of observational studies in epidemiology 
SKALP Skin-derived antileukoproteinase 
SGOT Serum glutamic-oxaloacetic transaminase 
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TBI Total Body Irradiation 
TBSA Total Body Surface Area 
T-cell Thymocyte (immune cell that needs thymus to mature) 
TCR T-cell receptor 
TGF-beta 1 Tumor growth factor beta 1 
Th1 T-cells of helper type 1 
Th2 T-cells of helper type 2 
Th17 T-cells of helper type 17 
TLR-4 Toll-like receptor 4 
Tnf Tumor necrosis factor 
TRALI Transfusion related acute lung injury 
UVA Ultraviolet light type A 
UVB Ultraviolet light type B 
VOD Veno-occlusive disease 
VZV Varicella Zoster Virus 
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1 INTRODUCTION TO THE FIELD 
1.1 WHY SEARCH FOR THE HOLY GRAIL OF TRANSPLANTION? 
To cure Leukemia has been a goal since the Greeks named the disease “White blood” - 
Leukemia. The noble-prize winning achievement of a stable protocol of allogenic bone-
marrow-transplantation by the Noble Laurate Thomas E.D. and the Seattle Group in the 
seventies gave transplantation firm ground (E. Thomas et al., 1975). However, today, four 
decades thereafter, the separation Graft-versus-host disease (GvHD) and Graft-versus-
leukemia (GvL) reactions, (anti-tumor immunity), remain as key issues to be solved. To find 
a well-defined strategy that separates these two events are widely acknowledged as the search 
for the “Holy Grail” of allogeneic stem cell transplantation.  
 
The data supporting transplantation has improved the last decade. In 2006, Appelbaum and 
Pearce suggested transplantation as the premium choice in the first untreated relapse of acute 
myeloid leukemia (AML), and, recent data suggests that the chance for cure is better than 
what could be seen in the classic Figure from Appelbaum and Pearce who set the chance for 
cure to 25% when BMT is utilized direct as a curative treatment for relapsed AML (Figure 
1). The patients with the best survival in this high risk disease were the patients with acute-
GvHD of grade II or more, in whom this severe disease must be associated with GvL 
(Appelbaum & Pearce, 2006; Gyurkocza, Lazarus, & Giralt, 2017).  
 
The number of transplantations can today be estimated to exceed 500.000 cases worldwide 
(Gratwohl et al., 2015). Pediatric patients who survive cancer have higher chances to live a 
long and healthy life (Asdahl et al., 2017). Retrospective data have pointed out that relapse is 
the major cause of treatment failure after transplantation. Studies have shown that 
myeloablative conditioning including higher dose of total-body irradiation is associated with 
an increased tumor eradication at the stake of a higher toxicity of liver, gut, and lung and an 
increased rate of severe acute-GvHD. Although acute-GvHD grade II or more is associated 
with a better relapse free survival in high-risk AML, GvHD is a major cause of death after 
transplantation (Gyurkocza et al., 2017; Nassereddine, Rafei, Elbahesh, & Tabbara, 2017). 
Allogeneic stem cell transplantation of acute-lymphoblastic leukemia (ALL) in first complete 
remission GvHD induces the most potent anti-tumor immunity through the induction of GvL 
(Inbar, Rowe, & Horowitz, 2017). Together, it is conceivable that acute-GvHD and the GvL 
are at least partly correlated/associated and/or connected. Therefore, it is a matter of uttermost 
importance for the treatment of leukemia to separate acute-GvHD and GVL i.e. to find the 
Holy-Grail of transplantation. 
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Figure 1. The classic Figure from Appelbaum F.R. et al. who set the chance for cure to 25% 
in a theoretical calculation when transplantation is utilized direct as a curative treatment for 
first untreated relapse of acute-myeloid leukemia 
 
 
 
 
 
Reprinted from Best Practice & Research Clinical Haematology, Vol.  19, Appelbaum F.R., 
Hematolpoietic cell transplantation in first complete remission versus early relapse,  pp. 333-
339. Copyright (2006), with permission from Elsevier 
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1.2 THE SYNGENEIC TRANSPLANTATIONS 
The syngeneic kidney transplantation was a breakthrough in the transplantation field 
(HarrisonM.J.P. & MurrayJ.H., 1955). Following in the footsteps of the successful syngeneic 
kidney transplantation, and in an attempt to find a sanctuary from the “secondary disease” 
(GvHD – and the more common Host-versus-graft disease (HvGD), when the immune 
defense of the patient rejects the graft); Thomas E.D. and colleagues proceeded on the path to 
cure acute-leukemia when they offered two children with leukemia and their families a 
possible cure with lethal irradiation aimed to destroy the leukemia and bone-marrow 
transplantation from the patients respective twin. Thomas and colleagues at Mary Imogene 
Bassett transplanted the first human with isologous marrow, referred from the Johns Hopkins 
Hospital in Baltimore, MD. This patient and the following patient referred from the Eglin Air 
Force Base Hospital, FL. survived their transplantation, but the leukemia relapsed (E. D. 
Thomas, Lochte, Cannon, Sahler, & Ferrebee, 1959). The conclusions were that there was 
additional means needed to cure leukemia beyond irradiation and that the isologous marrow 
did not prevent the leukemia from relapse. The authors discussed two sources of increased 
anti-leukemic treatment; first the addition of chemotherapy to the lethal irradiation to reduce 
the burden of leukemia further before rescuing the patient with a transplantation of bone 
marrow and then the potential anti-tumor effect seen in animal models of homologous 
transplantation. This effect had been discussed during the 1950’s, when an effect of the graft 
against the tumor was noted in experimental animal models, even more so when the number 
of leukemic cells in the recipient was small (Barnes, Corp, Loutit, & Neal, 1956; E. D. 
Thomas et al., 1959). 
 
1.3 SKIN GRAFT HISTOCOMPATABILITY AND GVL IN HUMAN 
Cutaneous immunization by skin grafts determined the tissue-antigen or the 
histocompatability between the donors and the recipient in the first transplantation where 
GvLwas experienced in human. In 1963, Mathé G. et al. searched for donors for a recipient in 
need of cure for acute-lymphoblastic-leukemia who had several relapses following 
chemotherapy treatments during several years. The Paris group determined histocompatibility 
by first transplanting a skin graft from the patient to the six donors who were in fact, the 
father, mother, sister, and the three brothers of the patient. The donors immunized and 
rejected the skin-graft in between 12 – 22 days. Thereafter, the donors received a skin-graft 
from all of the potential donors with the hypothesis, that the graft that was rejected the fastest, 
would be the one closest to the recipient since immunization against the recipient already was 
in place in that donor. One thing was certain after this procedure, that the donors where 
immunized against antigens in the patient’s skin.   
The patient received 800 rads from two opposing Co60 and was successfully transfused with 
330 mL of bone-marrow from each of the six donors. The transplantation of the patient was a 
five-hour transfusion procedure, during which he received a total of 2000 mL of blood with 
5.8 x 1010 mononucleated cells.  During the transfusion, 1700 mL blood was withdrawn from 
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the patient. He was kept in aseptic conditions in a room with ultraviolet light from the 23rd 
April – 4th July. During this time period, the patient experienced a severe GvHD with 
cutaneous, liver and gastrointestinal involvement that were treated with steroids. 
Furthermore, he had suspected lung-infiltrates that were successfully treated with isoniazid 
and isonicotinylhydrazide (INH) (900 mg/daily) and streptomycin (1 gram/day) in a similar 
treatment protocol as tuberculosis. 
On June 6th that corresponds to day 44 after SCT, the patient again received skin allograft 
from all donors. One of them remained perfectly intact for seven months; these others 
remained for 15 – 60 days. The brother who had the skin graft that remained intact was 
chosen for donor-lymphocyte-infusions, and during October the patient received weekly 
infusions of 29 - 45 x 106 nucleated cells, which revoked the graft-versus-host disease. The 
patient survived 12 months without signs of recurrent leukemia (Mathe et al., 1965).  
 
1.4 PHARMACOLOGICAL IMMUNOSUPPRESSION   
1.4.1 The barrier of graft-versus-host disease 
The GvHD and the HvGD remains a barrier within transplantation. However, patients who 
had received kidney transplants before the syngeneic transplants did not experience the 
immense type of rejection seen in the animal models, something the surgeons believed was 
mediated by immunosuppression, since the transplants were cadaver kidneys from patients 
with congestive heart failure and the recipients were in end-stage chronic uremia. From the 
moment this thought was evoked, and on, throughout the transplant field, the search for 
suitable immunosuppression to allow optimal post-transplant graft and patient survival, has 
been ongoing. In a canine model, especially methotrexate was found to be a promising 
prophylaxis against GvHD after transplantation. Thomas E.D. expressed his astonishment 
when he concluded that the anti-metabolite methotrexate that suppresses the bone marrow 
does not suppress the engraftment of bone marrow in dogs when the treatment started three – 
five days after transplantation (E. D. Thomas, Collins, Herman, & Ferrebee, 1962).  
1.4.2 The final candidates 
The development was not easy and a wide range of pharmaceutics was tried in several small 
and large animal models. After studies on several pharmaceutics in rodents, primates and 
canines, antithymocyte globuline (ATG), cyclophosphamide (Cy) and methotrexate (MTX) 
were identified as potential candidates for suppression of GvHD, and among these, 
methotrexate turned out to be an outstanding GvHD prophylaxis in the HLA-matched setting 
(Storb, Epstein, Graham, & Thomas, 1970; E. D. Thomas et al., 1971). The construction of a 
protocol with iterative doses of methotrexate to protect from the development of acute-GvHD 
opened up the possibilities to start transplants in human with siblings and unrelated matched 
donors - with the aim to cure hematological malignancies including leukemia. 
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1.5 THE CURE OF LEUKEMIA 
The stable Kaplan-Meier curve presented by the Seattle group in 1975 after addition  of 
cyclophosphamide in to TBI in the conditioning regimen and methotrexate as a GvHD-
prophylaxis made it possible to start to identify the clinical symptoms and signs necessary for 
a graft-versus-leukemia effect (E. Thomas et al., 1975). During the improvement of their 
protocol and their care, the survival increased each year towards a cure of Leukemia (Figure 
2). Research has subsequently tried to identify the time for the development of GvL, and if 
possible to separate this phenomenon from GvHD to offer a future cure for cancer with 
minimal adverse effects. 
1.5.1 Tumor immunity and clinical GvHD  
Initially, both acute-GvHD and chronic-GvHD were reported to be associated with GvL 
(Weiden et al., 1979; Weiden et al., 1981). In 1990, the International Bone Marrow 
Transplantation Register (IBMTR) could gather 439 patients transplanted for ALL, 1046 
patients transplanted for AML, and 769 patients transplanted for CML. The study had three 
key results. First, it was confirmed that GvL was mediated by T-cells in human i.e., the T-cell 
depleted recipients had a higher relapse rate. Second, GvL can result from major 
mistocompatibility complex (MHC) differences between the donor and the recipient as the 
syngeneic twins had the highest relapse rate. Third, the GVL effect was associated with 
GvHD (Horowitz et al., 1990). The major shortcoming of this study was that no landmark 
was used in the analysis which overrated the importance of chronic GvHD. The chronic-
GvHD is an event that comes when the hazard-ratio for treatment-failure, including early 
relapse, already has decreased. Thus, a landmark needs to be set at a time-point at least 100 
days after transplantation so that not all censored events e.g. treatment failure and relapse 
before the time-window when chronic-GvHD starts, not falsely indicate an increased 
modulation of the adoptive immunity during chronic-GvHD. This Landmark can be set at 
different time-points, one year has been used and six months have been used, dependent on 
what the outcome of the Study Is (Ringden et al., 2017; D. J. Weisdorf et al., 2009). In an 
attempt to determine if there can be a GvL effect in the absence of GvHD in patients 
transplanted for AML and ALL, 5200 autologous transplantations, where reinfusion of 
leukemic cells is a possibility, with 44% TBI as the conditioning regimen, were compared 
to1039 transplantations, without any GvHD and with 68% TBI in the conditioning. The two 
year relapse incidence was significantly lower in the allograft group in patients 27% ±2 vs. 
43% ±1 in autografts. This study cannot exclude a GVL effect in the absence of clinical 
acute-GvHD and point towards the possibility to separate GvHD and GVL (Ringden et al., 
2000). 
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Figure 2. Survival curves in patients (n=70) transplanted by a Human Leukocyte Antigen 
matched graft for acute leukemia during the development of the Seattle protocol.   
 
 
Open circles denote survivors. 
 
 
Reproduced with permission from E. Donnall Thomas, M.D., Rainer Storb, M.D., Reginald 
A. Clift, F.I.M.L.T., Alexander Fefer, M.D., F. Leonard Johnson, M.B., B.S., Paul E. 
Neiman, M.D., Kenneth G. Lerner, M.D., Harold Glucksberg, M.D., and C. Dean Buckner, 
M.D. Bone-Marrow transplantation (First of Two Parts), New England Journal of Medicine, 
Vol. 292 No. 16 pp. 832-843 Copyright Massachusetts Medical Society 
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1.5.2 Cutaneous acute-GvHD and anti-tumor immunity 
Cutaneous acute-GvHD was found to have a good GvL effect and was associated with 
chronic leukemia in the first chronic phase when the European group for Blood and Marrow 
Transplantation Registry (EBMTR) presented a study of more than1000 patients with a five 
year follow-up. The patients were transplanted between 1979 and 1990. The study postulated 
an anti-leukemic effect of cutaneous acute-GvHD in chronic leukemia (Gratwohl et al., 
1995). The important GvL effect caused by cutaneous acute-GvHD was confirmed in a study 
of 2122 patients with acute leukemia in first remission and 780 patients with chronic myeloid 
leukemia in first remission that received their first transplant from an HLA-identical donor. In 
the study, it was found that grade I acute GvHD, (acute GvHD covering 50% or less of the 
TBSA), was associated with a superior leukemia free survival (Ringden et al., 1996). 
1.5.3 The best donor 
In a re-classification of the degree of HLA-match from the study presented in 2002 by 
Weisdorf D.J. et al. of 2464 patients who received their transplant from unrelated donor, and 
450-HLA identical matched sibling transplantations, the findings of the previous study could 
be confirmed, HLA-mismatch do not increase the GvL effect in chronic leukemia 
significantly, the best matched donor is the best donor (D. J. Weisdorf et al., 2002; D. J. 
Weisdorf et al., 2009). 
1.5.4 Methotrexate and graft versus leukemia (GvL) 
Methotrexate confirmed the position in the graft-versus-host prophylaxis in 2012 when the 
IBMTR gathered 4022 patients who were transplanted in the period1997-2005 and received 
myeloablative conditioning without ex vivo T-cell depletion. No significant difference in 
relapse rate was observed between patients with or without GvHD. However, in this study 
compared to the previous study of Horowitz et al. combined calcineurin and methotrexate or 
mycophenolate mofetil (MMF) where more common, and a graft-versus-host prophylaxis 
with less GvL promoting effect than methotrexate alone and cyclosporine and methotrexate 
together may have had an impact on the results. Consequently, Chronic-GvHD and acute-
GvHD followed by chronic-GvHD had a decreased leukemia free 5 year survival 
(70%)/(64%) and a decreased overall survival (73%)/(65%) (D. Weisdorf et al., 2012). 
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1.6 IMMUNOLOGY OF CUTANEOUS ACUTE-GVHD 
1.6.1 Unrecognizable T-cells 
GvHD was first encountered after cardiac surgery and then termed postoperative 
erythrodermia (POE). In a fatal adverse event, six out of twelve recipients of sibling blood 
transfusion died in a transfusion associated GvHD (ta-GvHD), that started with a 
postoperative erythrodermia, i.e. a cutaneous acute-GvHD and spread to the liver and the 
gastrointestinal channel (Vriesendorp & Heidt, 2016). The risk for GvHD is increased in 
immunosuppressed patients, who cannot identify or defend themselves against the exogenous 
T-cells. Neonates are especially sensitive to ta-GvHD (Funkhouser et al., 1991). In blood 
transfusions of unirradiated blood between close relatives, there is a risk that the blood donor 
is homozygotous for a HLA-antigen where the recipient is heterozygotous. The result is that 
the recipient cannot identify and reject the donor T-cells in a host-versus-graft reaction; the 
recipient will instead die in a graft-versus-host reaction unleashed by the unrecognizable T-
cells without any hope of engraftment, - a blood transfusion does not contain enough stem-
cells. A donor homozygotous for HLA to a recipient heterozygotous for the same HLA, 
which can occur within the same family, is also a risk in solid organ transplantation, 
especially when recipients receive parts of a liver from a living donor within their own 
family. After transplantation, GvHD not seldom affects the skin, the whole gastrointestinal 
tract and the liver (Figure 3.), and may develop into multiorgan failure, why GvHD 
prophylaxis is used when donor T-cells encounter the antigens of the conditioned recipient 
after a transplantation (Ferrara, Levine, Reddy, & Holler, 2009; Rappeport, 1990; 
Vriesendorp & Heidt, 2016); (Zeiser et al., 2006). 
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Figure 3. GvHD mainly affect the skin, the whole gastrointestinal tract and the liver 
 
 
 
Reproduced with permission from Robert Zeiser, M.D., and Bruce R. Blazar, M.D. 2017; The 
New England Journal of Medicine, Vol 377 pp. 2167-2179 Copyright Massachusetts Medical 
Society 
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1.6.2 Tissue damage 
During the development of GvHD, the first step is an increased antigen presentation through 
an upregulation of human leukocyte antigens (HLA) on the cell surfaces of the patient. The 
increased density of antigens is triggered by the inflammation caused by the tissue damage 
inflicted by the conditioning regimen. The conditioning regimen increases the release of 
cytokines, the expression of adhesion molecules and HLA, as well as the damaged cells and 
cell components, in the skin, the liver, the lung and the gut. Furthermore, the tissues that are 
involved in the GvHD after transplantation may have been damaged by the previous medical 
history of the patient, i.e. by the underlying malignancy and the previous treatment thereof, 
and from the infections that are common in patients with hematological disease. These 
chronic- and acute injuries provide targets for the GvHD. The skin is more commonly 
affected by acute-GvHD compared to liver or gut (Antin & Ferrara, 1992; Ferrara et al., 
2009). The acute tissue damage can heal, and the inflammation may resolve, but several 
factors in the allogeneic setting change the immunomodulatory signals in the allogeneic 
setting, such as IL-10 polymorphism and vitamin D polymorphism, and increase or decrease 
the likelihood for GvHD (Lin et al., 2003; Middleton et al., 2002). 
1.6.3 T-cell activation and proliferation  
In addition to the antigen upregulation of step one, donor T-cells from the graft have to meet 
the antigen and be stimulated to proliferate. After transplantation, the grafted T-cells are 
recruited to the tissue by the chemokines and cytokines that are released from the tissue 
secondary to the damage caused by the conditioning regimen. The damaged tissue presents 
adhesion factors which enables the T-cells to enter the skin. By tissue inflammation, the T-
cells and the professional antigen presented cells (APC) are activated and drained to the local 
lymph nodes where they have a higher probability to meet. The secondary step in the 
development of acute-GvHD, the clonal expansion of donor naïve T-cells, does not necessary 
occur, but if the factors favoring a continued immune response are present, GvHD 
pathogenesis may progess. One such factor is the number of possible immunological 
synapses where the antigens are presented through HLA to the memory T-cells in a 
costimulatory environment (Curtsinger, Johnson, & Mescher, 2003; Isakov & Altman, 2012). 
HLA-class I is presented on almost all cells in the skin, but in an inflammatory situation 
HLA-class II is upregulated in the tissue too and presented on cells outside the hematopoietic 
lineage e.g. (B-cells, macrophages and dendritic cells). In contact with the HLA-molecule 
which presents an antigen epitope, the T-cell will recognize if it is foreign or not. In addition 
to the immunological synapse, the “second signal” decides if the T-cell will be activated, 
partially activated or go into anergy (shut down of response). In close proximity to the T-cell-
receptor (TCR) and the HLA is costimulatory molecules and ligands such as CD28 on the T-
cell and B7 on the professional antigen presenting cell. If both the stimulation through 
HLA:TCR and the co-stimulation, i.e. B7:CD28, is in place, the T-cell starts to accumulate 
and secrete IL-2 which binds to the IL-2 receptor in an autocrine mode and activates the T-
cell (Guinan E. 1995). The activated donor T-cells start to proliferate in the local lymph node. 
The release of IL-2 can also act to stimulate the presence of regulatory T-cells which can 
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inhibit the conventional T-cell response, this has been suggested to be an adverse effect of the 
calcineurin inhibitors (Zeiser et al., 2006). For CD8+ T-cells to proliferate, they need 
prolonged contact with the antigen in the immunological synapse, they need costimulation, 
but they also need a third cytokine signal. This signal can be either IL-12 which is produced 
by macrophages and dendritic cells secondary to the autocrine interferon-gamma from the 
activated donor T-cells. The third signal can also be IL-7 together with IL-18. Both IL-7 and 
IL-18 has been associated with the development of acute-GvHD (Dean et al., 2008; Shaiegan, 
Iravani, Babaee, & Ghavamzadeh, 2006). The combination is shown to induce proliferation 
of CD8+ T-cells together with costimulation and stimulation of the T-cell receptor (Walsh 
M.C. 2014). The possibility for activation of donor memory T-cells is increased with a more 
intense conditioning regimen, an increased number of APCs in the patient, an increased 
number of infused donor cells or a concomitant infection (Antin & Ferrara, 1992). The 
regulatory T-cells have been suggested to leave the skin in number after an immune response, 
where after they pass the local lymph node and recirculate to the skin to dampen the 
immunity (Tomura et al., 2010). 
1.6.3.1 Clinical application 
T-cell depletion of the graft (ex-vivo) or anti-thymocyte-globulin given during the 
conditioning regimen, (in-vivo-T-cell depletion), which decreases the number of T-cells in 
the graft was developed to decrease the second step in GvHD (Busca & Aversa, 2017; 
Marmont et al., 1991).  
1.6.4 Systemic inflammation 
Finally, the proinflammatory IL-2 activates the mononuclear cells graft to start to produce 
inflammatory cytokines, e.g., IL-1, tnf-alpha, and interferon-gamma. The T-cells continue to 
develop and traffic to the tissue where they induce cytotoxic cell death through Fas-ligand, 
Granzymes and Perforin. This lead to an increased level of tissue destruction and T-cell 
proliferation and lead to the severe cytokine storm of acute-GvHD (Antin & Ferrara, 1992; 
Ferrara et al., 2009). 
GvHD is a paradigm of systemic inflammation and in its more severe form threatens the life 
of the patient that enters multi-organ failure with symptoms coupled to the dysepitheliation 
caused by the tissue infiltrated cytotoxic T-cells. The organ failure becomes evident with 
massive diarrhea, icteric liver failure secondary to destruction of the biliary ducts and skin 
desquamation with increased fluid loss. The dysregulation of the immune-defense, the tissue-
damage and the immunosuppressive treatment all increase the risk for infections. The 
mortality is high. To diagnose GvHD early and correct, several biomarkers such as Elafin, 
interleukein-8, TNF-receptor 1, IL-2 receptor alpha, and Hepatocytic Growth Factor have 
been identified (Paczesny et al., 2010).  
Cutaneous acute-GvHD is indicated by an increase of Elafin/SKALP which is produced by 
the Keratinocytes in response to inflammation (Figure 4). Elafin has also been found to be an 
early marker in acute-respiratory distress syndrome (Paczesny et al., 2010; Wang et al., 
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2017). The Cytokines released during cutaneous acute-GvHD further include interleukin 8 
(Chang T.P. 2015), a proinflammatory cytokine, that is inhibited in response to TGF-beta 1. 
TGF-beta 1, in turn, is produced by CD4+ regulatory T-cells which are distinguished by the 
IL-2 receptor CD25. Tissues and cells that are activated or inflamed shed cytokine receptors, 
and some of these receptors have become markers of acute-GvHD e.g. TNF-receptor 1 and 
IL-2-receptor alpha. Shedding is suggested to protect against severe innate immune hyper 
reactivity (Xanthoulea et al., 2004). When the inflammation including the cell mediated 
immunity starts to damage the tissue, cell size in tissues decreases, which also increases the 
expression of factors such as Hepatocytic Growth Factor (HGF) which is released secondary 
to a decrease of the cell size of fibroblasts, a cell in the skin (Qin, Worthen, & Quan, 2017). 
The cytokines released also regulate the T-cell response, whereas IL-2 alpha stimulates a 
regulatory-T cell response, which balances the response to local antigens in the skin, and the 
contact between conventional T-cells and regulatory T-cells in the lymph node (Billroth-
MacLurg, Ford, Rosenberg, Miller, & Fowell, 2016). A dysregulation of the regulatory T-
cells are suggested to be present in acute-GvHD (Rieger et al., 2006), which may explain the 
elevated IL-8 levels. In this connection, therapies that increase the amount of regulatory-T-
cells in patients with GvHD are warranted.  
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Figure 4. Cutaneous acute-GvHD is indicated by an increase of Elafin / SKALP which is 
produced by the Keratinocytes in response to inflammation 
 
 
From Sophie Paczesny, Thomas M. Braun, John E. Levine, Jason Hogan, Jeffrey Crawford, 
Bryan Coffing, Stephen Olsen, Sung W. Choi, Hong Wang, Vitor Faca, Sharon Pitteri, Qing 
Zhang, Alice Chin, Carrie Kitko, Shin Mineishi, Gregory Yanik, Edward Peres, David 
Hanauer, Ying Wang, Pavan Reddy, Samir Hanash, James L. M. Ferrara, 2010: Elafin Is a 
Biomarker of Graft-Versus-Host Disease of the Skin; Science Translational Medicine, Vol. 2 
pp. 1-13, Reprinted with permission from AAAS.  
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1.6.5 Clinical Cutaneous acute-GvHD from Th1 paradigm to Th17 presence 
T-helper cells are CD4+ cells that direct the immune response by the secretion of cytokines 
and by cell-to-cell contact were primarily categorized to two cell phenotypes. The Th1 CD4+ 
cells are distinguished by the production on IL2 and IFN-gamma and the Th2 by IL-4 and Il-
10. For twenty years Th1 and Th2 were the only two known types of T-helper cells, where 
CD4+Th1 cells promoted cell-mediated-immunity and CD4+Th2 cells supported a 
development of B-Cells, antibodies and the defense against parasites. Today, the CD4+ 
subpopulations have expanded and in addition toTh1 and Th2 cell types, the CD4+CD25+ 
regulatory T-cells and CD4+Th17 cells have been identified by the production of interleukin-
17 and interkeukin-22, which are is important for the immunity in the parenchyma. The 
increased knowledge has triggered a re-evaluation of the Th1 paradigm that dominated 
cutaneous acute-GvHD. The conditioning regimen does impact the development of CD4+ 
cells as well as the CD8+ cells why it is important to relate the clinical research of the 
cytokine pattern and the T-helper balance to the clinical protocol used. Preferably, the T-
helper response and the cytotoxic T-cell response should be studied during cutaneous acute-
GvHD after different conditioning regimen whereafter the results should be compared 
between the clinical protocols e.g. the response after RIC compared to the response after 
myeloablative regimen, this is not the case in the reports found. 
The cytokine profile and the cytotoxic involvement has been evaluated in three studies with 
predominantly myeloablative conditioning. In a study of HLA-identical sibling transplants 
(n=22), given after a Cyclophosphamide and a TBI based myeloablative conditioning with 
cyclosporine and methotrexate as GvHD prophylaxis, IFN-gamma, IL-1, and IL-6 were 
expressed by the circulating lymphocytes. In the cutaneous acute GvHD, the skin was 
infiltrated by lymphocytes, which expressed low levels of genes encoding for IL-1 and IL-6, 
but neither a Th1 (IL-2/IFN-gamma) nor a Th2 (IL-4/IL-10) cytokine phenotype was present 
in this organ (Carayol et al., 1997). In unrelated donors, TNF-alpha, IFN-gamma, and IL-10 
were elevated in serum in patients with acute GvHD II-IV compared to patients with mild 
cutaneous acute GvHD. The theory that cytotoxic T-cell killing is a major mediator of acute-
GvHD is strengthened by that the Fas Ligand was increased on the CD8+ cells in patients 
with acute GvHD in the related setting and in the serum of unrelated recipient (Lee et al., 
1997; Remberger, Jaksch, Uzunel, & Mattsson, 2003). However, the FasL increased also in 
patients who converted to donor-chimerism after unrelated transplantation (Remberger et al., 
2003), why Fas L may be a major pathway to eradicate the remaining recipient cells.  
The possible Th17 involvement in cutaneous acute-GvHD was evaluated in a study with an 
even mix of related (18/36) and unrelated transplants (18/36), the majority with an 
myeloablative conditioning regimen, cyclophosphamide and busulfan in (16/36) and 
cyclophosphamide and TBI in (9/36), with (35/36) on methotrexate and cyclosporine GvHD 
prophylaxis. The prospective nature of the study made it possible to sample skin biopsies 
before prednisolone was started. Immunohistochemistry reviled low levels on IL-17 and IL-
22 producing CD4+Th17 cells in the skin. Instead, a three weeks cell cultures on 3D matrix 
after skin punch biopsies showed a CD4+ IFN-gamma positive profile (Broady et al., 2010).  
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On the contrary, there are two studies with mixed myeloablative and reduced-intensity 
conditioning that report an IL-22 phenotype in acute-GvHD (Bruggen et al., 2014; Reinhardt 
et al., 2014). In the latter, a study designed to evaluate a phagocyte dependent induction of the 
Th17 response in acute-GvHD, the cutaneous and gastrointestinal GvHD was followed and 
sampled during fourteen days. In the study of 47 patients; 35/37 children and 12/47 adults, a 
majority with related matched or unrelated donors, and a minority with haploidentical and 
mismatched unrelated donors - with a reduced intensity conditioning (Bacigalupo, 2004); the 
CD4+ peripheral blood monocytes released IL17 and IFN-gamma upon toll-like-receptor 
type-4 (TLR4) stimulation by S100 which is produced by phagocytes. This finding suggested 
a link between the development of Th17 response, bacterial infection and the emergence of 
GvHD (Reinhardt et al., 2014). 
Viral proteins have also been used to modulate the CD4+ population. In a murine in-vivo 
model the human immunodeficiency virus (HIV) protein gp-120 was used to stimulate the 
potency of regulatory T-cells which attenuteted GvHD (Schloder, Berges, Tuettenberg, & 
Jonuleit, 2017). 
1.6.6 The time dependent changes of cell populations and cytokines in 
cutaneous acute-GVHD 
It is important to know the time pattern in the immunological changes in the skin during 
cutaneous acute-GvHD in order to be able to choose the right clinical response to the disease. 
The normal healthy epidermis constitutes a distinct T-cell compartment with a predominant 
memory effector T-cell phenotype (Spetz, Strominger, & Groh-Spies, 1996). After 
transplantation, the immune reconstitution of the lesion and non-lesion skin in patients have 
been followed in sex-mismatched recipients utilizing fluorescent in situ hybridization (FISH) 
to discriminate between donors and recipients - while immunohistochemistry was used to 
identify the changes in the cell population. Already at day fourteen after a myeloablative TBI 
transplant, the intradermal CD1a+ Langerhans cells were depleted. Donor derived cells 
approached the dermis as early as day 23+. Lesions of acute GvHD was mediated primarily 
by CD8+ T-cells, and in non-lesion skin, the CD1a+ seem do dominate in this minor-HY 
mismatched setting (Stewart R.L. 2017). 
The acute-GVHD incidence is dependent on the degree of HLA-A, -B, (-C) and HLA-DRB1 
match between the donor and the recipient. The important HLA-DRB1 is expressed on the 
APCs, and while the HLA-class II molecules are constitutively present on the hematopoietic 
cells (monocytes, dendritic cells, and B-cells) they can be upregulated on a range of tissues 
after inflammation. The Class I HLA-A, -B, and -C function as the presentation module of 
antigens for the nucleated cells. In acute cutaneous GvHD, skin infiltrating T-cells seem to 
accumulate with an increase in recipient-specific epitopes present on donor-T-cells. In 
clinical cutaneous acute-GvHD, a multitude of epitopes from an antigen mismatch elicit the 
concomitant response from CD4+ and CD8+ T-cells (Thus et al., 2015). 
Immunohistochemistry revealed that CD4+ cells appeared more frequently in the dermis and 
CD8+ cells in the epidermis. Furthermore, a mismatch in the class II HLA and HY-
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presenting infiltrate was associated with a more pronounced CD4+ infiltration, while a class I 
HLA and HY-presenting infiltrate was associated with CD8+ infiltration. This was revealed 
by Predicted Indirectly ReCognizable Epitopes (PRICHE), which is a term for peptides 
presented at HLA that differs from the donor-self derived epitope (Thus et al., 2015). Weeks 
after the start of clinical cutaneous acute-GvHD, in a group of 15 patients, the majority on 
methylprednisolone treatment after an acute-GvHD of the skin, (11/15) with a TBI based 
conditioning, compared to (2/8) in the control group with Bu-Cy in their conditioning, 
(p=0.039, Fishers two-tailed test), the CD8+ population in the skin did not have any 
chemokine ligands on them. The chemokine receptors were more common on the CD4+ 
population (CD4+ CR10+ and CLA+ cells) (Faaij et al., 2006). This suggest later arrival or a 
more transient presence of the different CD4+ cells in the dermis where they can enter and 
release their cytokines to steer the CD8+ cells in the epidermis. 
In a prospective study where six out of seven patients with myeloablative conditioning 
developed cutaneous acute-GvHD, acute-GvHD initiated release of interferon-gamma and 
interleukin-10 into the bloodstream. The patients have received grafts from HLA-identical 
donors and received a methotrexate and cyclosporine GvHD prophylaxis. However, 
interleukin-12 or interleukin-4 could not be detected at any level of disease which may 
depend on the detection threshold (ELISA after -80 oC freezing &thawing). Both Th1 
(CD4+Interferon-gamma+ cells) and Th2 (CD4+Interleukin-4+ cell) activity was increased. 
Specifically, interleukin 10 –levels increased with hepatic disease severity (Yeh S.P 2012). 
This suggest that different organ involvement can be coupled to different cytokine prophiles, 
which may switch during the time-course of the acute-GvHD when the organ involvement 
changes. 
1.6.7 The antigen presenting cells and the regulation of the immune 
response 
Knockout animal models suggest that highly efficient antigen presenting cells (APCs); the 
dendritic cells from the recipient; initiates the acute-GvHD through cell to cell contacts with 
the T-cells in the graft. The effect may however not be totally dominant and may possibly be 
overruled by the total amount of antigen and receptor contacts, and thus may be revoked e.g., 
by a large number of T-cells in the graft (Shlomchik et al., 1999). In human, several types of 
dendritic cell have been identified. In the skin, the Langerhans cell population which is a part 
of the CD1a+ population, and the CD14+ APCs are dominated populations (Angel et al., 
2007). In human, the dendritic cell populations, including the Langerhans cell population 
express the CD1a, CD1b and CD1c lipid antigen presenting molecules which may be 
associated to the HLA-1 and T-cell interplay. Interestingly, while the CD1c is more efficient 
in cross presentation, the CD1a may be involved in the induction of tolerance, since the loss 
of CD1a cell surface expression is not associated with conventional immune defects 
(Kashem, Haniffa, & Kaplan, 2017). The conditioning regimen damages the skin and heavily 
damages the cells within the lymphocytoid cell populations, of which a large part does not 
survive but enters necrosis and/or apoptosis. That certainly occurs due to the soluble factors 
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and the direct contact between activated apoptotic cells and antigen-presenting-cells 
upregulate molecules on the APC that are costimulatory to the T-cells e.g. CD80 and CD86 
(S. K. Pathak et al., 2012). The fact that the recipient dendritic cells at large have left the skin 
at day 14 after transplantation, points out that the antigen specific priming of the donor T-
cells that venture to the skin to elicit acute-GvHD possibly is done elsewhere. It is well 
known that the dendritic cells of the skin travel to the local lymph node where they mediate 
and appropriate immune response which may include the facilitation of a clonal expansion of 
T-cells (Angel et al., 2009). The damaged host dendritic cells may also be necessary for the 
suppressive action of donor-derived regulatory T-cells (Kushwah, Oliver, Zhang, 
Siminovitch, & Hu, 2009). A plausible model is that early in the process, that leads to lesion 
cutaneous acute-GvHD, the patient is at the mercy of the interplay between the donor T-cell 
population which favors an aggressive and an suppressive function, - and the host-antigen 
presenting cells. This theory suggests that the aggressive or suppressive outcome of this 
interplay determines if an acute-GvHD will be elicited or not. One way tolerance towards and 
antigen response can be mediated is by the work of regulatory T-cells. A meta-analysis on the 
graft composition finds that a higher ratio of regulatory T-cells in the infused graft is 
associated with an increased overall survival, specifically decreased non-relapse mortality, 
probably to a decreased acute GvHD (Fisher et al., 2017). The clinical studies of infusions of 
regulatory T-cells before- and after transplantation support a role where regulatory T-cells 
may balance the ability of T-cells to induce acute-GvHD (Brunstein et al., 2011; Di Ianni et 
al., 2011).   
1.6.8  The keratinocyte and it´s key role in cutaneous immunity 
The keratinocyte, the epithelial cell of the epidermis, has a key role in cutaneous immunity. 
At the damaged epithelial surface, these cells produce cationic antimicrobial peptides (AMPs) 
and precursors of interleukin-1 alpha and interleukin-1 beta. A study of delayed 
hypersensitivity (DTH) after topical application of skin sensitizers, like poison ivy, found that 
the keratinocytes were already activated when the T-cells entered the skin (Griffiths & 
Nickoloff, 1989). When activated, the keratinocytes release cytokines from the 
inflammosome and chemokines which attract T-cells. With increasing inflammation, and 
after particularly after stimulation by The Th17 T-cell produced cytokines IL-17A and IL-22, 
the keratinocytes increase their AMP production (Liang et al., 2006). Acute-GvHD models 
have revealed that the keratinocytes function as non-professional APCs. Keratinocytes may 
produce IL-1, IL-6, IL-10, IL-18 and tumor-necrosis-factor alpha and upregulate MHC class-
II (HLA-class II). These cells cannot themselves launch a T cell-mediated immune response, 
but they seem to be able to process and present peptides derived from the outside of the cell 
membrane to CD8+ cells and guide them to target cell lysis.  The keratinocytes of the skin are 
also able to present peptide antigens to CD4+ cells which in turn may induce Th1 and Th2 
type cytokines (Nestle, Di Meglio, Qin, & Nickoloff, 2009). 
 
28 
and the direct contact between activated apoptotic cells and antigen-presenting-cells 
upregulate molecules on the APC that are costimulatory to the T-cells e.g. CD80 and CD86 
(S. K. Pathak et al., 2012). The fact that the recipient dendritic cells at large have left the skin 
at day 14 after transplantation, points out that the antigen specific priming of the donor T-
cells that venture to the skin to elicit acute-GvHD possibly is done elsewhere. It is well 
known that the dendritic cells of the skin travel to the local lymph node where they mediate 
and appropriate immune response which may include the facilitation of a clonal expansion of 
T-cells (Angel et al., 2009). The damaged host dendritic cells may also be necessary for the 
suppressive action of donor-derived regulatory T-cells (Kushwah, Oliver, Zhang, 
Siminovitch, & Hu, 2009). A plausible model is that early in the process, that leads to lesion 
cutaneous acute-GvHD, the patient is at the mercy of the interplay between the donor T-cell 
population which favors an aggressive and an suppressive function, - and the host-antigen 
presenting cells. This theory suggests that the aggressive or suppressive outcome of this 
interplay determines if an acute-GvHD will be elicited or not. One way tolerance towards and 
antigen response can be mediated is by the work of regulatory T-cells. A meta-analysis on the 
graft composition finds that a higher ratio of regulatory T-cells in the infused graft is 
associated with an increased overall survival, specifically decreased non-relapse mortality, 
probably to a decreased acute GvHD (Fisher et al., 2017). The clinical studies of infusions of 
regulatory T-cells before- and after transplantation support a role where regulatory T-cells 
may balance the ability of T-cells to induce acute-GvHD (Brunstein et al., 2011; Di Ianni et 
al., 2011).   
1.6.8  The keratinocyte and it´s key role in cutaneous immunity 
The keratinocyte, the epithelial cell of the epidermis, has a key role in cutaneous immunity. 
At the damaged epithelial surface, these cells produce cationic antimicrobial peptides (AMPs) 
and precursors of interleukin-1 alpha and interleukin-1 beta. A study of delayed 
hypersensitivity (DTH) after topical application of skin sensitizers, like poison ivy, found that 
the keratinocytes were already activated when the T-cells entered the skin (Griffiths & 
Nickoloff, 1989). When activated, the keratinocytes release cytokines from the 
inflammosome and chemokines which attract T-cells. With increasing inflammation, and 
after particularly after stimulation by The Th17 T-cell produced cytokines IL-17A and IL-22, 
the keratinocytes increase their AMP production (Liang et al., 2006). Acute-GvHD models 
have revealed that the keratinocytes function as non-professional APCs. Keratinocytes may 
produce IL-1, IL-6, IL-10, IL-18 and tumor-necrosis-factor alpha and upregulate MHC class-
II (HLA-class II). These cells cannot themselves launch a T cell-mediated immune response, 
but they seem to be able to process and present peptides derived from the outside of the cell 
membrane to CD8+ cells and guide them to target cell lysis.  The keratinocytes of the skin are 
also able to present peptide antigens to CD4+ cells which in turn may induce Th1 and Th2 
type cytokines (Nestle, Di Meglio, Qin, & Nickoloff, 2009). 
  29 
1.6.9 The histopathology of acute-GvHD 
1.6.9.1 Elafin a biomarker of GvHD 
The GvHD biomarker, Elafin is predictive of non-relapse-mortality. Elafin is an AMP which 
also is known as proteinase 3 inhibitor (PI3) or Skin-derived antileukoproteinase (SKALP),  
and is expressed by polymorphnuclear leukocytes and squamous epithelia. The proteinase 
inhibiting domain protects against detachment mediated by polymorphonuclear leukocyte 
(PMN) derived enzymes such proteinase 3 and elastase (Levine et al., 2012; Paczesny et al., 
2010). The serine protease inhibitor was discovered in keratinocytes of the human 
hyperproliferative epidermis. The proteinase is linked to multiple domains which bind to 
extracellular and cell envelope proteins through transglutaminase substrates at the NH2 
terminal. Elafin is expressed in epithelia that are exposed to inflammatory stimuli such as the 
hair follicular of the skin, the vagina and the oral cavity (Pfundt et al., 1996). Elafin is also a 
biomarker for ARDS (Sallenave et al., 1999; Wang et al., 2017). It is expressed by squamous 
epithelia and is present in many suprabasal layers in the upper gastrointestinal tract 
(Esofagus). The esophageal lining has multiple positive cell layers and the superficial layers 
stain polarized and intense. In the suprabasal layer, Elafin colocalizes with type 1 
transglutaminase (Pfundt et al., 1996). The esophagus has a high constitute expression of 
elafin (Hosaka et al., 2008), in the lower levels of the gastrointestinal channel may induce 
elafin in response to antimicrobial invasion (Wehkamp, Schmid, & Stange, 2007). 
1.6.10 The gastrointestinal disease and its relation to the cutaneous disease 
In transplantation patients there is a concomitant development of cutaneous acute-GvHD and 
gastrointestinal acute-GvHD to a high degree >50% (Martin et al., 1990). Acute 
gastrointestinal GvHD is the most common cause of gastrointestinal persistent nausea and 
anorexia after transplantation (Wu et al., 1998). If it is possible to do an endoscopic 
assessment, gastrointestinal disease are confirmed by histological grading. A routine 
histopathology protocol is compromised by fixation of tissue by 10% of buffered formalin. 
The specimens are assessed on three sections where inflammation, necrosis of epithelial cells 
(single cell necrosis), epithelial atypia, loss of glands or crypts, dilatation of glands or crypts, 
crypt obstruction and abscesses are rated. In the small intestine, the status of the villous 
architecture is described additionally. Cytoreductive therapy before allogeneic transplantation 
may leave histological changes which are similar to the pathology of GI acute-GvHD, 
therefore histological studies have included patients after day 20, generally or in subgroups 
(Roy et al., 1991; Snover et al., 1985).   
Single cell necrosis is the established positive biopsy finding of gastrointestinal acute-GvHD 
(Snover et al., 1985). At autopsy, rectal biopsies present single cell necrosis, crypt 
degeneration, crypt obliteration and crypt abcesses (Sale G. 1979). If cytolomegalovirus 
(CMV) inclusions can be identified by peroxidase-antiperoxidase techniques the GvHD of 
the gastrointestinal tract cannot be diagnosed histologically, with reliability (Snover et al., 
1985). The confounding by CMV can be the cause why the early study of Snover et al. with 
 
 29 
1.6.9 The histopathology of acute-GvHD 
1.6.9.1 Elafin a biomarker of GvHD 
The GvHD biomarker, Elafin is predictive of non-relapse-mortality. Elafin is an AMP which 
also is known as proteinase 3 inhibitor (PI3) or Skin-derived antileukoproteinase (SKALP),  
and is expressed by polymorphnuclear leukocytes and squamous epithelia. The proteinase 
inhibiting domain protects against detachment mediated by polymorphonuclear leukocyte 
(PMN) derived enzymes such proteinase 3 and elastase (Levine et al., 2012; Paczesny et al., 
2010). The serine protease inhibitor was discovered in keratinocytes of the human 
hyperproliferative epidermis. The proteinase is linked to multiple domains which bind to 
extracellular and cell envelope proteins through transglutaminase substrates at the NH2 
terminal. Elafin is expressed in epithelia that are exposed to inflammatory stimuli such as the 
hair follicular of the skin, the vagina and the oral cavity (Pfundt et al., 1996). Elafin is also a 
biomarker for ARDS (Sallenave et al., 1999; Wang et al., 2017). It is expressed by squamous 
epithelia and is present in many suprabasal layers in the upper gastrointestinal tract 
(Esofagus). The esophageal lining has multiple positive cell layers and the superficial layers 
stain polarized and intense. In the suprabasal layer, Elafin colocalizes with type 1 
transglutaminase (Pfundt et al., 1996). The esophagus has a high constitute expression of 
elafin (Hosaka et al., 2008), in the lower levels of the gastrointestinal channel may induce 
elafin in response to antimicrobial invasion (Wehkamp, Schmid, & Stange, 2007). 
1.6.10 The gastrointestinal disease and its relation to the cutaneous disease 
In transplantation patients there is a concomitant development of cutaneous acute-GvHD and 
gastrointestinal acute-GvHD to a high degree >50% (Martin et al., 1990). Acute 
gastrointestinal GvHD is the most common cause of gastrointestinal persistent nausea and 
anorexia after transplantation (Wu et al., 1998). If it is possible to do an endoscopic 
assessment, gastrointestinal disease are confirmed by histological grading. A routine 
histopathology protocol is compromised by fixation of tissue by 10% of buffered formalin. 
The specimens are assessed on three sections where inflammation, necrosis of epithelial cells 
(single cell necrosis), epithelial atypia, loss of glands or crypts, dilatation of glands or crypts, 
crypt obstruction and abscesses are rated. In the small intestine, the status of the villous 
architecture is described additionally. Cytoreductive therapy before allogeneic transplantation 
may leave histological changes which are similar to the pathology of GI acute-GvHD, 
therefore histological studies have included patients after day 20, generally or in subgroups 
(Roy et al., 1991; Snover et al., 1985).   
Single cell necrosis is the established positive biopsy finding of gastrointestinal acute-GvHD 
(Snover et al., 1985). At autopsy, rectal biopsies present single cell necrosis, crypt 
degeneration, crypt obliteration and crypt abcesses (Sale G. 1979). If cytolomegalovirus 
(CMV) inclusions can be identified by peroxidase-antiperoxidase techniques the GvHD of 
the gastrointestinal tract cannot be diagnosed histologically, with reliability (Snover et al., 
1985). The confounding by CMV can be the cause why the early study of Snover et al. with 
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patient inclusion between 1981-1983 where cytolomegalovirus was diagnosed on clinical 
suspection show a positive predictivity (0.55) for gastrointestinal acute-GvHD by cutaneous 
acute-GvHD in patients with biopsies made between 20 – 100 days after transplantation i.e. 
cutaneous acute-GvHD may predispose for gastrointestinal acute-GvHD, but not for 
gastrointestinal CMV infection. This study shows a correlation between diarrhea and 
gastrointestinal disease of the small intestine and correlation between positive biopsies of the 
small intestine and the rectum. The patients with upper gastrointestinal acute-GvHD more 
often had symptoms with nausea, vomiting, and anorexia (Snover et al., 1985). Thus 
gastrointestinal disease can be present in a part or the whole of the gastrointestinal tract. 
The association between cutaneous acute-GvHD beyond stage one and upper GI acute-GvHD 
was presented by Roy et al. in 1991 in a retrospective study of allogeneic stem cell 
transplantation recipients. The combined measure of a significant gastrointestinal biopsy from 
the upper and the lower intestine acquired at day 38 and day 40 after transplantation resulted 
in 16/26 patients with cutaneous acute GvHD grade II or more with a positive gastrointestinal 
acute-GvHD histology, and 10/26 with a negative - compared to the 51 patients with no- or 
stage 1 cutaneous acute-GvHD of whom 18/51 patients had a positive biopsy and 33/51 
patients had a negative biopsy (Roy et al., 1991). These results in a specificity of 0.77 and a 
predictive positive value of 0.62 of acute cutaneous GvHD grade II or more for patients with 
a positive GI biopsy. In specific, there was a significant association between a cutaneous 
acute-GvHD with a rash that covered more than 25% of the TBSA and GvHD was stronger 
than the association between upper and lower acute-GvHD GI biopsies with positive 
histology.  
The relation between cutaneous acute-GvHD and the GI acute-GvHD can also be found in a 
study where the median time to intestinal biopsy by endoscopy was 54 days (range 21-98). In 
this retrospective study where 15/40 (38 %) of the patients with a biopsy proven GI acute 
GvHD also had cutaneous rash, while 2/40 (5%) with skin rash did not have GI acute-GvHD, 
the endoscopic evaluation of gastrointestinal acute-GvHD was prompted by diarrhea (70%), 
27/40 or nausea and vomiting in 28/40, (67%). All patients with ulceration had GI GvHD, 
while a normal endoscopy could not exclude GI acute GvHD. The biopsies were examined 
immunohistochemically, and viral cultures were made, in addition to the hematoxylin and 
eosin staining (Sultan, Ramprasad, Jensen, Margolis, & Werlin, 2012). This reveals a 
specificity rate of 0.75 and a positive predictive value of 0.88 for cutaneous acute-GvHD. 
 
The high incidence of concomittant cutaneous- and GI acute-GvHD is supported 
prospectively. In total 76 patients entered a study after two weeks of symptoms of nausea, 
vomiting, and anorexia (15.4 +- 11.4 days), at a mean of 57 days after transplantation (+- 31 
days). The symptoms were evoked during a taper of prednisone in 23 of the patients who 
already had acute-GvHD if the skin and/or liver or skin, liver and intestine. The majority had 
T-cell depleted grafts and received a myeloablative conditioning. Acute-GvHD was the single 
cause of symptoms in 83%, 63/76. Intestinal upper endoscopy biopsies were performed in 52 
out of these 63 patients. At this time point, the majority, 51/52 patients had edema and patchy 
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erythema of the gastric antral mucosa, with a pathology that ranged from, “scattered, isolated 
crypt cells”, to “lymphocytic infiltrate in the lamina propria associated with crypt drop-out 
and apoptotic cells” (Wu et al., 1998).  
In a study with patients of 273 patients included between 1996 and 2001, Schulenburg et al. 
presented the main disease panorama in patients with symptoms of the GI tract after 
allogeneic transplantation as GvHD as; (62%), gastritis/esophagitis; (19%), CMV; enteritis 
(11%); bacterial enteritis (6%); toxic mucosal damage (2%) (Schulenburg et al., 2004). CMV 
enteritis is seen during 100 days after transplantation and may be prevented with acyclovir 
(Meyers et al., 1988), and treatment start early after transplantation or at engraftment with 
ganciclovir may be monitored and guided by pp65 antigen and quantitative PCR (Boeckh et 
al., 1996; Schulenburg et al., 2001). An association between liver acute-GvHD and 
gastrointestinal acute-GvHD was not seen in the histological studies by Roy et al. and Fischer 
et al. (Roy et al., 1991); (Fischer et al., 2015). Treatment of GI disease of a disease severity 
beyond II has since 1997 included 2 mg/ body weight and a topical addition of budenoside (9 
mg/day orally) (Schulenburg et al., 2004). 
1.6.11 Regulatory T-cells is scarce and CD8+ T-cells common in the 
gastrointestinal GvHD  
The hypothesis of a dysregulation of the regulatory response in acute-GvHD was supported 
in a retrospective study of 95 paraffin-embedded tissue samples from duodenum and colon 
biopsies of 49 patients. In this study where the majority (46/49) had matched related or 
unrelated transplant with an cyclosporine and methotrexate or melphalan GvHD-prophylaxis 
with the addition of anti-thymocyte globuline in case of an unrelated transplant, (25/49) had 
myeloablative conditioning divided on TBI (n=17/25) and chemotherapeutics (n=8/25); the 
ratio of CD8+ and regulatory T-cells revealed by double immunoenzymatic staining in 
mucosal biopsies was highly significant (Figure 5) for gastrointestinal acute-GVHD (Rieger 
et al., 2006).  
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Figure 5. The ratio of CD8+ and regulatory T-cells as revealed by double immunoenzymatic 
staining in mucosal biopsies was highly significant for gastrointestinal acute-GVHD  
 
 
Republished with permission of American Society of Hematology, from Mucosal FOXP3+ 
regulatory T cells are numerically deficient in acute and chronic GvHD, Kathrin Rieger, 
Christoph Loddenkemper, Jochem Maul, Thomas Fietz, Daniel Wolff, Harald Terpe, Beate 
Steiner, Erika Berg, Stephan Miehlke, Martin Bornhäuser, Thomas Schneider, Martin Zeitz, 
Harald Stein, Eckhard Thiel, Rainer Duchmann, and Lutz Uharek, volume 107, pp. 1717-
1723, 2006; permission conveyed through Copyright Clearance Center, Inc.  
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1.6.12 The liver disease and its relation to the cutaneous disase 
The liver is perceived as the organ with a relatively low incidence of acute-GvHD compared 
to the skin and the gut. In an analysis of 1986 patients after myeloablative conditioning and a 
GvHD prophylaxis with methotrexate or methotrexate and cyclosporine in a majority of the 
patients, (37%), (740/1986) had acute-GvHD and the incidence of acute-GvHD of the liver 
was the lowest (19%), (369/1986). Among the patients with acute-GvHD in any organ did 
50% did have liver involvement, compared 54% with acute-GvHD of the gut, and 81% had 
GvHD of the skin (Martin et al., 1990). In later studies of secondary treatment with 
monoclonal antibodies, high liver involvement in severe acute-GvHD has been suggested as a 
reason to inferior results, e.g. 52% liver involvement and 17% six months survival (Horse 
derived Anti-thymocyteglobulin) (Khoury et al., 2001), 50% liver involvement and 0% six 
months survival (Alemtuzumab) (Martinez et al., 2009), 32% liver involvement and 28% six 
months survival (Dacluzimab) (Perales et al., 2007). Consensus of histopathological 
pathognomous findings for liver acute GvHD is missing, but a recent report suggests that 
within the portal field, bile duct damage and bile duct intraepithelial lymphocytes may be 
indicative of liver GvHD in general (Eskandari et al., 2017).  
1.6.13 The lung disease and its relation to the cutaneous disease 
The lung function detoriates after transplantation and in both the population surviving acute-
GvHD. In a post-mortem Study In patients who received myeloablative conditioning, a 
correlation between onset of pulmonary disease and onset of acute GvHD within 150 days 
was found, together with a post-mortem association of bronchopneumonia or extensive acute 
broncitis and acute GvHD grade II-IV, has been reported (Figure 6.), (Beschorner, Saral, 
Hutchins, Tutschka, & Santos, 1978). Recovery of lung-function comes late, among 180 days 
survivors of acute-GvHD grade I-IV, an improvement in lung-function (FVC and TLC) could 
be seen first 1.5 years after Transplantation (Gore, Lawton, Ash, & Lipchik, 1996). Today, 
the majority of the lung diseases after transplantation are grouped in a syndrome called 
interstitial pneumonia syndrome (IPS) (Table 1). IPS has an incidence of 3-15% after 
myeloablative conditioning (Panoskaltsis-Mortari et al., 2011).  
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Figure 6. In patients who received myeloablative conditioning, a correlation between onset 
of pulmonary disease and onset of acute GvHD within 150 days was found, together with a 
post-mortem association of bronchopneumonia or extensive acute broncitis and acute GvHD 
grade II-IV. 
 
 
 
 
 
Reproduced with permission from William E. Beschorner, M.D., Rein Saral, M.D., Grover 
M. Hutchins, M.D., Peter J. Tutschka, M.D., and George W. Santos, M.D., 1978: 
Lymphocytic bronchitis associated with graft-versus-host disease in recipients of bone-
marrow transplants; The New England Journal of Medicine, Vol. 299 pp. 1030-1036 
Copyright Massachusetts Medical Society 
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TABLE 1. 
DEFINITION OF IDIOPATHIC PNEUMONIA SYNDROME 
I: Evidence of widespread alveolar injury: 
 a. Multilobar infiltrates on routine chest radiographs or computed tomography 
 b. Symptoms and signs of pneumonia (cough, dyspnea, tachypnea, rales) 
 c. Evidence of abnormal pulmonary physiology 
  1. Increased alveolar to arterial oxygen difference 
  2. New or increased restrictive pulmonary function test abnormality 
II: Absence of active lower respiratory tract infection based upon: 
 a. Bronchoalveolar lavage negative for significant bacterial pathogens including acid-fast 
bacilli, Nocardia, and Legionella species 
 b. Bronchoalveolar lavage negative for pathogenic nonbacterial microorganisms: 
  1. Routine culture for viruses and fungi 
  2. Shell vial culture for CMV and respiratory RSV 
  3. Cytology for CMV inclusions, fungi, and Pneumocystis jirovecii (carinii) 
  4. Direct fluorescence staining with antibodies against CMV, RSV, HSV, VZV, 
influenza virus, parainfluenza virus, adenovirus, and other organisms 
 c. Other organisms/tests to also consider: 
  1. Polymerase chain reaction for human metapneumovirus, rhinovirus, coronavirus, 
and HHV6 
  2. Polymerase chain reaction for Chlamydia, Mycoplasma, and Aspergillus species 
  3. Serum galactomannan ELISA for Aspergillus species 
 d. Transbronchial biopsy if condition of the patient permits 
III: Absence of cardiac dysfunction, acute renal failure, or iatrogenic fluid overload as 
etiology for pulmonary dysfunction 
Definition of abbreviations: CMV = cytomegalovirus; HSV = herpes simplex virus; RSV = 
respiratory syncytial virus; VZV = varicella zoster virus. 
Table updated from Clark J.G.H.J., Hertz M.I., Parkman R., Jensen L., Peavy H.H., 
Idiopathic pneumonia syndrome after bone marrow transplantation. Am Rev Respir Dis 
1993;147:1601–1606. Reprinted with permission of the American Thoracic Society. 
Copyright © 2011 American Thoracic Society. Panoskaltsis-Mortari A. Griese M. Madtes 
D.K. Belperio J.A. Haddad I.Y. Folz R.J. Cooke K.R. 2011; An official American Thoracic 
Society research statement: noninfectious lung injury after hematopoietic stem cell 
transplantation: idiopathic pneumonia syndrome. American Journal of Respiratory and 
Critical Care Medicine; Vol. 183, pp. 1262-1279 The American Journal of Respiratory and 
Critical Care Medicine is an official journal of the American Thoracic Society. 
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There is no controversy over the immunological impact transplantation has on the lung, but 
the presence or not of a lung cute-GvHD is discussed, and the histopathological definition 
IPS encompasses what may be lung GvHD. TBI is one major cause of pulmonary toxicity 
and decrease in function. Infections are another cause, and it is very important to diagnose 
pulmonary disease early to initiate proper treatment of infections in the immunosuppressed 
individual (Hoglund, Sandin, & Simonsson, 2015; Svensson, Lundstrom, Hoglund, & Cherif, 
2017). 
 
Due to the lack of histopathological studies of lung GvHD within the first hundred days, the 
pattern of lung pathology within the first five months of transplantation in two studies is 
described (Xu, Drachenberg, Tavora, & Burke, 2013; Yousem, 1995). 
There are few reports where the relation of cutaneous acute-GvHD can be related to what is 
described as a concomitant GvHD in the lung. The clinical spectrum of disease is categorized 
by the presumed site of tissue injury (Table 2) (Panoskaltsis-Mortari et al., 2011). In a 
histopathological study of transbronchial or open lung biopsy specimens, out of 17 described 
patients, four specimens were from <5 months after GvHD. The remaining specimens were 
from median 12 months after transplantation (range 6-110). Special microbial stains (Grocott, 
acid fast, Gram) and bacterial, fungal and viral cultures were negative. The two patients with 
GvHD of the skin both were on steroid treatment and had specimens from the fourth month, 
and thus possible had originated together with a cutaneous acute-GvHD. These patients were 
both females and were transplanted for CML. The biopsies revealed BO and Bronchiolitis 
obliterans organizing pneumonia (BOOP), both were alive at follow-up, one with no sign of 
pulmonary disease at six months, and one with pulmonary disease at 39 months. The patient 
with BOOP presented with dyspnea on exertion, cough, and malaise. The chest X-ray show 
“patchy bilateral alveolar and interstitial infiltrates”.  The morphology of the small airways in 
showed “epithelial apoptosis” and “epithelial transmigration of lymphocyte”. Granulation 
that filled the airways was seen in all specimens, which was accompanied by perivascular and 
mononuclear infiltrates. There was an “up-and-down” pattern of epithelial regeneration, with 
“stretches of cuboidal cells alternating with hyperplastic tall columnar epithelium”. The 
patient with cicatrial bronchiolitis obliterans (BO), were grouped with five others, in a group 
who had “airways obliterated by dense fibrous scar tissue”. Two of the patients with 
bronchiolitis obliterans had post pulmonary transplantation biopsies. Three had perivascular 
and interstitial mononuclear cells. All had the “up-and-down” pattern of the epithelia and the 
“peribronchial mononuclear infiltrate percolated into the overlying epithelium, where 
apoptosis was readily noted” (Yousem, 1995). 
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TABLE 2. 
CATEGORIZATION OF THE CLINICAL SPECTRUM OF LUNG INJURY 
FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION 
Clinical Spectrum of Disease as Categorized by Presumed Site of Primary Tissue 
Injury 
 
Pulmonary Parenchyma Vascular Endothelium Airway Epithelium 
Acute interstitial 
pneumonitis (AIP)* 
Peri-engraftment 
respiratory distress 
syndrome (PERDS)* 
Cryptogenic organizing pneumonia 
(COP)/Bronchiolitis obliterans 
organizing pneumonia (BOOP)* 
Acute respiratory distress 
syndrome (ARDS)* 
Noncardiogenic capillary 
leak syndrome (CLS)* 
Bronchiolitis obliterans syndrome 
(BOS)* 
BCNU pneumonitis Diffuse alveolar 
hemorrhage (DAH)* 
 
Radiation pneumonitis Pulmonary veno-
occlusive disease 
(PVOD) 
 
Delayed pulmonary 
toxicity syndrome 
(DPTS)* 
Transfusion-related acute 
lung Injury (TRALI) 
 
Post-transplant 
lymphoproliferative 
disease (PTLD) 
Pulmonary cytolytic 
thrombi (PCT) 
 
Eosinophilic pneumonia 
(EP) 
Pulmonary arterial 
hypertension (PAH) 
 
Pulmonary alveolar 
proteinosis (PAP) 
Pulmonary 
thromboembolus (PTE) 
 
*Conditions routinely included under the classification of idiopathic pneumonia syndrome 
(IPS). 
 
Reprinted with permission of the American Thoracic Society. Copyright © 2017 American 
Thoracic Society. Panoskaltsis-Mortari A. Griese M. Madtes D.K. Belperio J.A. Haddad I.Y. 
Folz R.J. Cooke K.R. 2011; An official American Thoracic Society research statement: 
noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia 
syndrome. American Journal of Respiratory and Critical Care Medicine; Vol. 183, pp. 1262-
1279 The American Journal of Respiratory and Critical Care Medicine is an official journal 
of the American Thoracic Society. 
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A recent study of another 17 specimens had four specimens from <5 months after 
transplantation, three of these had concomitant cutaneous GvHD, the rest were from median 
17 months (range 6-82). In this study, viral and bacterial etiologies were excluded by culture, 
diagnostic findings and special stain (Gomori methenamine silver, acid fast bacillus, 
cytomegalovirus, herpes simplex virus). These were distributed in different groups based on 
bronchiolar histology. The first categorized in the “acute-lung- injury pattern”, was a 60 y.o. 
male who died within 6.5 months after transplantation, The second was categorized as a 
histological obliterative bronchiolitis “OB-pattern”, the 40 y.o. female with ground glass 
densities with bilateral nodulus on CT, who complained of shortness of breath, had a GvHD 
that included the skin and the oral cavity, thereafter the pulmonary function were reported 
stable at three months but the GvHD recurred and she died of systemic GvHD at 1 y.  The 
third, a 49 y.o. female was categorized as a chronic interstitial pneumonia (CIP-pattern), and 
had shortness of breath with nodules and organizing pneumonia (OP), (CT). She had 
concomitant GvHD of the stomach, duodenum the liver and the skin. She stabilized, but died 
in multi-resistant staphylococcus aureus (MRSA) infection after having developed 
bronchiolitis obliterans syndrome (BOS). The histological pattern is diverse, but the mean 
bronchiolar CD3 cells/50 respiratory cells were 30 +-10 (SD) and all but one patient (16/17) 
in the study had apoptotic bodies, (one were autologous), (Xu et al., 2013). 
The clinical improvement of reduced-intensity conditioning (RIC) leads to a decreased tissue 
damage (Giralt et al., 1997) and thus less acute-GvHD and IPS, was developed secondary to 
the high incidence of GvHD and IPS in patients over 40 yrs old (Ringden et al., 1993). RIC 
has made transplantation possible with low toxicity (Ringden et al., 2013). 
1.6.14 The balance between GvHD and GvL 
In GvHD, the tissue damage from T-cell mediated cell lysis recruits additional immune cells. 
With increasing inflammation, the tissue destructive process is spreading, and the cross-
presentation between activated immune cells and the antigen presenting cells are increased. 
The oligoclonal response of activated T-cells in cutaneous acute-GvHD are evident and a 
multitude of clonal T-cells lines from a single skin biopsy can be visual already at five days 
in a T-cell cloning assay (Gaschet et al., 1996). Without proper treatment, this process of 
oligoclonal expansion of recipient antigen specific T-cells may become fatal to the patient. 
However, if the cutaneous tissue lesions of GvHD do not progress, or can be controlled by 
anti-GvHD therapy, the presence of GvHD is associated with a decreased incidence of 
recurrent malignant disease (Ringden et al., 2000). There are indications that the GvL effect 
is coupled antigen mismatches between the donor cells and the malignancy of recipient 
origin, predominantly in the related donor-recipient pair (Hobo et al., 2013; Spierings et al., 
2013). Thus, the anti-tumor immunity associated with cutaneous acute-GvHD in human may 
be mediated by adoptive immunity towards minor histocompatibility antigens. A plausible 
model which is congruent with long term cancer free survival is that after the priming of an 
antigen specific memory T-cell response, antigen specific memory T-cells with tissue 
specificity patrol the patient and eradicate remnant tumor (Woodland & Kohlmeier, 2009). 
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1.7 DEFINITION OF ACUTE-GVHD 
The organ damage is staged and categorized by the Glucksberg Criteria and the IBMTR 
classification (Glucksberg et al., 1974; Rowlings et al., 1997). 
1.7.1 Stage of organ involvement 
The clinical manifestation and the histopathological changes in organ involvement as staged 
by Glucksberg: 
“Skin: +1, A maculopapular eruption involving less than 25% of the body surface; +2, a 
maculopapular eruption involving 25-50% of the body surface; +3, generalized erythroderma 
with bullous formation and often with desquamation. 
Liver: +1, Moderate increase of SGOT (150-750 IU) and bilirubin (2.0-3.0 mg/100 ml); +2, 
bilirubin rise (3-5.9 mg/100 ml) with or without an increase in SGOT; +3 bilirubin rise (6-
14.9mg/100 ml) with or without an increase in SGOT; +4, bilirubin rise to >15 mg/100 ml 
with or without an increase in SGOT. Increases in SGOT were temporarily related to the 
onset or worsening for skin rash. 
Gut: Diarrhea, nausea, and vomiting were graded +1 to +4 in severities, and the severity of 
gut involvement was assigned to the most severe involvement noted. It was difficult to 
quantitate most of these manifestations except for diarrhea. 
Diarrhea: +1, >500 ml of stool/day; +2, >1,000 ml of stool/day; +3, >1,500 ml of stool/day; 
+4, >2,000 mL of stool/day.”(Glucksberg et al., 1974).   
The Total Body Surface Areas (TBSA) affected by cutaneous acute-GvHD can be 
determined by the “rule of nines”. The area of surface in the body parts in the adult is 9% for 
the head, 9% for each arm, chest & back 18% each, 1% for genitalia and 18% for each leg. In 
the children, the surface area of the head is 19% at birth, but 1% shall be derived each year 
until ten year of age, and instead, be added to the legs. In children, each arm is 9% and the 
thorax is 36%, while the legs start at 13% each (Waslen, 1986).  
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1.7.2 Severity of GvHD 
“Based on severity and number of involved organs, patients were divided into four 
categories: 
Grade 1: +1 to +2 skin rash without gut involvement with no more than +1 liver involvement; 
no decrease in performance status or fever. 
Grade 2: +1 to +3 skin rash with either +1 to +2 gastrointestinal involvement or +1 to +2 liver 
involvement, or both. All exhibited a mild decrease in performance status and some had 
fever. 
Grade 3: +2 to +4 skin rash with +2 to +4 gastrointestinal involvement with or without +2 to 
+4 involvement. All exhibited a marked decrease in performance status and many 
experienced fever. 
Grade 4: Pattern and severity of GvHD similar to grade 3 with extreme constitutional 
symptoms.” 
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1.7.3 The histopathological grading 
Skin; 
Grade 1: the mildest change in the skin was focal or diffuse vacuolar degeneration of 
epidermal basal cells and acanthocytes.  
Grade 2: in addition to basal vacuolar degeneration, focal or diffuse spongiosis (separation of 
basal cells and acanthocytes by intercellular edema) and dyskeratosis or eosinophilic 
degeneration of epidermal cells which tended to occur in scattered individual cells.  
Grade 3: clefts and spaces after necrosis of basal cells and acanthocytes in the basal and more 
superficial layers often resulting in separation of the dermal-epidermal junction.  
Grade 4: frank loss of epidermis. 
Gut;  
Grade 1. The mildest changes in the gastrointestinal tract were focal dilatation and 
degeneration of the mucosal glands.  
Grade 2: the bowel, in addition to the changes described under grade 1, showed focal to 
diffuse loss of intestinal glands.  
Grade 3: focal mucosal denudation. 
Grade 4: diffuse mucosal denudation. 
Liver; 
Although hepatic GvHD causes variable degeneration and eosinophilic necrosis of 
hepatocytes, the most constant finding was that of degeneration and necrosis of small bile 
ducts.  
Grade 1: less than 25% pathological changes in small bile ducts. 
grade 2: 25-49%;  
grade 3: 50-74%;  
grade 4: more than 75%. 
Above are quotations from page 297, from the first and second paragraph in Glucksberg H. et 
al. (Glucksberg et al., 1974). The corresponding levels of bilirubin in micromole are: liver. +1 
< 34: +2, 34-102; +3: 103-255; +4: > 255. The CIBMTR revised the scoring and suggested 
following groups based on the staging by Glucksberg: A: stage +1 skin; B: stage +2 skin or 
stage 0-2 skin and stage 1-2 visceral acute GvHD (liver and/or gut); C: stage +3 of any 
skin/liver or gut; D: stage 4 of any skin/liver or gut (Rowlings et al., 1997). 
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1.7.4 Immune-mediated and cytotoxic assault of the lung  
The view of non-infectious lung damage as an idiopathic syndrome has changed into a view 
where the lung is considered to be under a complex immune-mediated and cytotoxic assault 
after transplantation. The mortality remains as high as 60-80% and above 95% in 
mechanically ventilated patients (Panoskaltsis-Mortari et al., 2011); (Fukuda et al., 2003). 
The gut-liver- lung axis is predominant in the experimental animal models referred to in the 
official statement, and treatment directed against Tnf-alpha is suggested. The American 
thoracic society (ATS) now defines Idiopathic Pneumonia Syndrome (IPS) accordingly: 
“An idiopathic syndrome of pneumopathy in which infectious etiologies and cardiac 
dysfunction, acute renal failure, or iatrogenic fluid overload has been excluded. Moreover, 
IPS has been further classified into specific entities” … “ based in large part on the primary 
anatomical sites of inflammation and dysfunction”. It is defined clinically by widespread 
alveolar injury, absence of infection and absence of cardiac, renal or iatrogenic ethiology 
(Panoskaltsis-Mortari et al., 2011).  
IPS should be differentiated by bronchoalveolar lavage (BAL), Computer tomography (CT), 
echocardiography and lung biopsy into specific entities mainly related to: Interstitial tissue, 
vascular tissue, airway tissue and IPS, unclassifiable (Table 1&2) (Panoskaltsis-Mortari et al., 
2011).   
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1.8 IS THERE A TIME WINDOW TO SEPARATE GVL FROM GVHD 
The time window for the elicidation of cell-mediated immunity evoked against leukemia was 
studied by Saltztein and Bortin in the beginning of the seventies. They suggested that critical 
time to catch the cells and to transfer the allogeneic GvL response was during the first week 
(6 days) (Bortin, Rimm, & Saltzstein, 1973; Saltzstein, Glasspiegel, Rimm, Giller, & Bortin, 
1972). The experimental setup was accordingly, in murine model experiments, the 70 days 
survival of secondary recipients was measured and related to the day of transplantation of 
splenic or lymph-node derived cells from primary recipients (normal AKR (H-2k) mice). The 
primary mice had been previously seeded with spleen cells harvested from AKR mice dying 
from long-passage lymphocytic leukemia, thereafter treated with TBI and cyclophosphamide 
and selected to an intervention by adoptive immunotherapy by inoculations by allogeneic BM 
cells or lymph-node cells from C57BL/6 (H-2b) or not. The 70 days survival of the secondary 
recipient peaked on day 6 compared to day 4 and 8. This suggests that in non-
immunosuppressed mice, the optimal day for cell harvesting from spleens and lymph-nodes 
to catch cells vital to transfer the allogeneic graft-versus-leukemia effect after the initiation of 
an immune response into a secondary host is at day 6 (Saltzstein et al., 1972).   
In a follow up experiment where adoptive immunotherapy was the exclusive anti-leukemic 
treatment; leukemic cells were transferred to primary hosts of different strains; at day six their 
spleens were harvested and transferred to a secondary recipient and the 60 day survival was 
tested. A significant GvL effect was found when the secondary recipient differed from the 
primary recipient in the H-2 locus (Bortin et al., 1973). This confirms that at day six, the anti-
leukemic priming of an unprimed immune response has taken place and further suggests that 
an antigen mismatch on one locus increases the GvL effect possibly by cross-presentation or 
increased danger signaling. 
In another murine model, Sadeghi et al. studied the kinetics of the elicitation phase of GvHD. 
In these studies reciepient female BALB/c mice received busulfan (80 mg/kg) for 4 days 
followed by cyclophosphamide (200 mg/kg) for 2 days as myeloablative chemotherapy, 
followed by syngeneic transplantation and allogeneic transplantation of male C57BL/6 mice. 
These experiments show an early peak of CD11c+ dendritic cells in the spleen followed by a 
major peak of CD8+ cells at day seven (Sadeghi et al., 2010). The time windows similar to 
that presented in the studies of GvL and GvHD by Saltztein et al. and Bortin et al. and 
suggest that GvHD and the GvL may be parallel processes in murine model.  
1.9 THE ROLE OF CONDITIONING REGIMEN 
1.9.1 Three reasons for conditioning before transplantation 
Transplantation has been considered an optional treatment, for several hematological 
malignancies, after a clinical risk-benefit decision and informed consent of the procedure has 
been acquired by the patient and in the cases of children, the whole family of the patient. In 
order to facilitate the transplantation procedure, patients are treated with total body irradiation 
with or without high doses of chemotherapy (conditioning regimen) prior to allogeneic stem 
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cell transplantation. The conditioning regimen is, in general, a combination of myeloablative 
and immune supervise treatment that serves several aims; First to decrease the risk for host-
versus-graft reaction which rejects the graft and prevents the engraftment in the primary and 
secondary hematopoietic organs of the recipient; The second purpose of the conditioning 
regimen may be to eradicate a malignant residual cells; The third purpose may be 
immunomodulatory, e.g. to decrease the risk for graft-versus-host disease while preserving 
the graft-versus-leukemia reaction, or to decrease the risk for host-versus-graft reaction while 
preserving the innate immunity. One immunomodulatory option of the graft is to give in-vivo 
T-cell depletion by using anti-thymocyte globulins.   
1.9.2 Myeloablative conditioning 
A myeloablative conditioning can be reached through several established clinical protocols. 
Total-body-irradiation (TBI) is a mainstay and may at higher dose ranges alone make the 
recipient susceptible for engraftment of the transplanted graft. The use of TBI in patients may 
induce adverse effects within the acute-irradiation-syndrome (ARS) and irreversible chronic 
damage to the lung. The TBI may be given as a single (920 – 1000 cGy) or by fractionated 
doses with repeated lower doses which limits the secondary tissue injuries but increases the 
accumulated irradiation e.g. dose 1320 cGy (Brochstein et al., 1987; E. D. Thomas et al., 
1977; Vriesendorp & Heidt, 2016). Irradiation of dual Co60 source gives a homogenous 
radiation exposure e.g. 5.5 rads/min – 8.0 rads/min, in a field where the patient has more 
marginal to move (E. D. Thomas et al., 1977). Linear accelerators can provide higher dose 
rates and linear irradiation is easier to shield (protect) the lungs, but where the patient is 
immobilized (Giebel et al., 2014). To cure leukemia chemotherapeutic agents are added to 
TBI as the doses needed to eradicate leukemia by TBI alone would induce lethal damage in 
the patient. Reduced intensity conditioning (RIC) may use DNA-synthesis blocking agents 
such as fludarabine and may be necessary in the older population or in patients with a 
previous medical history who do not sustain the toxicity of the myeloablative conditioning 
(Aschan, 2007; Slavin et al., 1998). 
1.9.3 Cyclophosphamide 
Cyclophosphamide is an effective immunosuppressive and anti-neoplastic agent. The 
maximum tolerated dose is 200 mg/kg limited by the side effect of hemorrhagic myocarditis. 
The protocol used in the majority of the patients in this thesis was cyclophosphamide for two 
days before TBI at a dose of 60 mg/kg/day in a central venous line (Ringden et al., 1996). 
Protocols used were developed and verified by several centers, but the protocols vary, and it 
is unlikely that to centers use the exact same protocol.  
1.9.4 Busulfan 
Busulfan is a myeloablative alkylating agent, which may substitute total-body-irradiation in 
myeloablative protocols. The nonmyeloablative cyclophosphamide are then used with the 
myeloablative Busulfan (a metabolite of treosulfan), in accumulated doses of 120 mg/kg and 
16 mg/kg (Ringden et al., 1999). The treatment at Center for Allogeneic Stem Cell 
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transplantation (CAST) was optimized and intravenous and monitored by plasma 
concentration measurements to reach the targeted steady-state to optimize the effect versus 
the adverse effects of the treatment (Hassan et al., 2002). Cyclophosphamide and TBI has a 
potentially better overall tumor effect but may lead to secondary malignancies and irradiation 
injuries of the lung. The cyclophosphamide and busulfan protocol lead to permanent alopecia 
and an increase risk for obstructive bronchiolitis, veno-occlusive-disease in the liver and 
hemorrhagic cystitis (Aschan, 2007; Ringden et al., 1999). 
1.9.5 T-cell depletion 
The in-vivo T-cell depletion used was by different anti-thymocyte globulins. The use of anti-
thymocyte globulins increases the number of patients that can be offered a transplantation as 
the in-vivo T-cell depletion lowers the risk for GvHD after transplantations with grafts from  
matched unrelated donors (MUD). The use of anti-thymocyte globulins also decreases the 
risk for graft-rejection in heavily transfused recipients, which may be a remnant to the era of 
non-filtered blood-products (Aschan, 2007).  In-vitro and in-vivo T-cell depletion has made it 
possible to choose grafts from donors in registers worldwide which has increased the 
possibility to locate suitable donor fast. 
1.10 THE HISTOCOMPATABILITY  
1.10.1 The barrier 
The allogeneic hematopoietic stem-cell transplantation (AHSCT) is transplantation within the 
human species between genetically disparate individuals. The transplantation faces the 
bidirectional barrier of host-versus-graft disease and graft-versus-host disease. The barrier 
can be estimated by comparing the degree of human-leukocyte-antigene (HLA)-match after 
tissue typing and genotyping of the HLA-genes for both recipient and donor (Olerup & 
Zetterquist, 1992; E. Thomas et al., 1975). The functional magnitude of the barrier may be 
assessed by the mixed-lymphocyte-reaction, intracellular ATPase activity of selected 
immuncells which are established for CD4+ T-cells, Limited Dilution tests, Tetramer analysis 
which is prevalent for CD8+ T-cells or enzyme-linked immunospot which is a common 
measure of interferon-gamma (Jeras, 2002; Mehrotra, Leventhal, Purroy, & Cravedi, 2015). 
The HLA-bind antigens and present them on the cell surface so that the antigen can be 
recognized by an antigen-specific T-cell receptor on T-cells. There are a high degree of 
polymorphism among the HLA-genes within the 7.6 Mb region where the HLA-A, -B, -C, -
DR, -DQ and -DR are transcribed. The HLA-barrier is minimum in syngeneic twins, among 
siblings there is a 48% chance of a HLA-match (Petersdorf, 2007; E. Thomas et al., 1975). 
NK-cells can be mediate cytotoxicity in addition to T-cells if the patient does not have killer 
cells immunoglobulin receptors (KIRs) which match HLA class I donor alleles (Farag, 
Fehniger, Ruggeri, Velardi, & Caligiuri, 2002). 
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1.10.2 Related transplantation 
Recipients not related to the donor, have a higher risk for graft-failure with an increased 
donor-recipient mismatching why the least mismatched donor should be selected in related 
transplantation (Anasetti et al., 1989). Further, there must not be a mismatch in the 
homozygotous locus of a related recipient homozygotous for HLA, as this is associated with 
a high risk of host-versus-graft disease. Further, pre-transplant cytotoxic cross-matching 
should be performed, as HLA-antibodies increase the risk for graft-failure (Petersdorf, 2007; 
E. Thomas et al., 1975).  
1.10.3 Unrelated transplantation 
In unrelated transplantation the risk for graft-failure and GvHD is higher with antigen 
mismatch than with allele mismatch. NK-cell alloreactivity give lower GvHD and lower 
relapse after specific conditioning and immunosuppression regimens, KIR-ligand 
incompatability can be used to select the donor of a graft with the beneficiary NK-cell effect 
(Petersdorf, 2007). In unrelated donors, the chance for a match is low and international 
cooperation is needed to find a donor in time from the international registries. Since 1987 the 
NIH has demanded a 5 – 6 match in the HLA-A, HLA-B and HLA-DRB1 loci in unrelated 
donors (Hurley et al., 2003). 
1.11 THE TRANSPLANTATION 
1.11.1 Trilinear engraftment by bone-marrow-transplantation 
The transplantation must provide trilinear engraftment of erythrocytes, immune-cells, and 
platelets. The graft is given to the conditioned patient as a transfusion during several hours 
under the direct supervision of a specially trained team comprising physicians and nurses. 
The day and time-point for the transplantation in relation to the conditioning regimen given is 
crucial for patient survival. The number of nucleated cells in the graft is a surrogate of 
hematopoietic stem cells and lymphocytes which are decisive to reach a successful 
engraftment. The Bone-Marrow is harvested in multiple aspirations under general anesthesia 
(E. D. Thomas et al., 1971).  
1.11.2 The nucleated cell dose 
A nucleated cell dose of above 3x108 cells/kg marrow has been identified as a key number to 
achieve a stable engraftment with a minimum degree of graft-versus-host disease in sibling 
and in syngeneic donor-recipients of bone-marrow-grafts (BM) (Barrett et al., 2000; Ringden 
& Nilsson, 1985). The crucial number in unrelated matched transplants has been suggested to 
3.65x108/kg (Sierra et al., 1997). Immunohistochemistry has revealed that in allogeneic stem 
cell transplantation not only the progenitor cells are important for engraftment. The increased 
use of peripheral-blood-stem-cells (PBSC) mobilized to the peripheral blood of the donor by 
using G-CSF provides grafts not only rich for in CD34+ progenitor cells but also CD3+ and 
CD56+ cells. The CD34+ count in BM is usually about 50% of the count found in PBSC, and 
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the CD3+ and the CD56+ is about 10% of the PBSC dose, yet transplantation outcome 
remain similar regardless of stem cell source (Remberger et al., 2001). 
1.11.3 The CD34+ cell dose  
Retrospective analysis of HLA-identical transplantations where positive selection of 
hematopoietic progenitor CD34+ cells have caused to depletion of CD3+ cells (T-cells) 
showed that the CD3+ T-cells are needed in a minimum of 0.2 x 106 cells/kg to prevent from 
graft-failure (Urbano-Ispizua et al., 2001). In a comparative study by Professor Remberger 
M. et al. from CAST and two additional European centers, which included 107 patients who 
received BM and 107 patients who received PBSC, - the CD34+ threshold (time in days) to 
achieve three consecutive days with an absolute neutrophil count (ANC) of 0.5x109 
(neutrophil engraftment) was lower than the platelet engraftment. The neutrophil engraftment 
was reported to be at day 19 (range 10 -– 31 days), in the BM-recipients, compared to the 
PBSC-recipients where ANC-engraftment was reached at day 15 (range 7-27 days), four days 
earlier, and the platelet engraftment (A week with platelet counts > 30 x 109/L without 
transfusion), was 27 days (range 18-210 days) in BM-recipients, compared to 20 days (range 
8-395 days) in PBSC recipients (Remberger et al., 2001). The optimal dose range of CD34+ 
in the PBSC graft was suggested to be (4 – 8x106 cells/kg) but may be wider (2.5 – 11x106 
cells/kg) where a higher number may decrease the overall survival secondary to GvHD 
(Sierra et al., 1997); (Remberger et al., 2015).    
1.12 THE ROLE OF GRAFT-VERSUS-HOST PROPHYLAXIS IN 
TRANSPLANTATION OUTCOME 
1.12.1 The methotrexate protocol   
To overcome the histocompatibility barrier remaining after the HLA-matching it is necessary 
to treat the recipient with an immunosuppressive prophylaxis in order to prevent from GvHD.  
In HLA-matched siblings, a methotrexate protocol elaborated in canine models preserves 
engraftment in human while decreasing GvHD (Storb et al., 1970; E. D. Thomas et al., 1971). 
The methotrexate GvHD-prophylaxis protocol was shown to preserve a substantial graft-
versus-leukemia effect that is needed to cure leukemia (E. Thomas et al., 1975; Weiden et al., 
1979). The introduction of cyclosporin A in connection with therapeutic drug monitoring 
provided an alternative to methotrexate. However, while the lung-toxicity decreased, an 
increased relapse incidence was observed with cyclosporine A instead of methotrexate 
(Atkinson et al., 1988; Backman, Appelkvist, Ringden, & Dallner, 1988).   
1.12.2 Cyclophosphamide postransplantation 
The action of drugs on tolerance is not the same before and after allogeneic transplantation. 
The use of post-transplant cyclophosphamide which has made Haploidentical-transplantation 
possible in a large scale is an example of that. There are two theories to why posttransplant 
cyclophosphamide induces tolerance. Initially, the theory was that cyclophosphamide given 
in the allogeneic setting deleted the proliferating donor-T-cells after transplantation (Mayumi 
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et al., 1987). Recently, however, it has been suggested that the donor T-regulatory cell are 
more resistant to cyclophosphamide given after transplantation than the conventional T-cells 
(Ganguly et al., 2014). In analogue, methotrexate was found by Thomas E.D. to have an 
effect as GvHD-prophylaxis while preserving GvL (E. D. Thomas et al., 1971). Recently, 
however, methotrexate has been suggested to work as a pharmaceutic substitute for a 
dysfunctional regulatory function (Talme, Bergdahl, & Sundqvist, 2016). Therapies and 
drugs may have regulatory effects after allogeneic transplantation with outcomes on GvL and 
GvHD than expected, why the timing of the use of therapies after transplantation is 
important. Haploidentical transplantation with a three day post-transplant cyclophosphamide 
graft-versus-host prophylaxis is now an established way of transplantation, with the 
advantage that donors can be found to a much larger extent within the family (Luznik et al., 
2008). 
1.12.3 Different prophylaxis in different leukemias 
The hard outcome measure of graft-versus-host prophylaxis must be treatment-failure. The 
combined treatment with a short-term methotrexate added to cyclosporin A weakens the 
barrier between the graft and the host at the cost with less acute-GvHD at the cost of a 
somewhat higher rate of relapses compared to methotrexate alone. Different graft-versus-host 
prophylaxes have different toxicity, different effects on acute-GvHD and chronic GvHD and 
effect on GVL. In children with acute or chronic leukemia who received a HLA-matched 
sibling graft after a Cyclophosphamide and TBI conditioning, none of these GvHD 
prophylaxes seem superior. In adults, generally, methotrexate has a pulmonary toxicity and is 
associated to the interstitial pneumonia syndrome, but preserves the graft-versus-leukemia 
effect best in ALL, when compared to cyclosporin A and MTX added to cyclosporine A, 
while cyclosporine A is superior in AML, while methotrexate and cyclosporine is superior in 
CML (Ringden et al., 1993). 
1.12.4 The Calcineurin inhibitors 
The calcineurin inhibitor cyclosporin and methotrexate is superior to tacrolimus and 
methotrexate and is the established alternative for GvHD prophylaxis. The criticism against 
the calcineurin inhibitors is that cyclosporin is nephrotoxic while tacrolimus is neurotoxic and 
that they inihibit IL-2 which leads to a decrease in CD4+CD25+FoxP3 regulatory cells, 
which theroretically may increase chronic GvHD that is a great problem for quality of life 
after transplantation (Storb, Antin, & Cutler, 2010).  
1.12.5 Myelotoxic suppressors 
To potentially myelotoxic drugs; sirolimus and mycophenolate has been tried in combination 
instead of cyclosporine and mycophenolate. Sirolimus that bind to the FK-binding protein 12 
and form a complex with mammalian target for rapamycin (mTOR) arrests the cell cycle in 
G1 through inhibition of DNA-transcription. Mycophenolate mofetil (MMF) inhibits inosine 
monophosphate dehydrogenase. The combination has been observed in a study with reduced 
intensity conditioning (RIC) in high-risk leukemia without inferior results beyond a later 
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ANC take. In one study with myeloablative busulfan conditioning which resulted in a pre-
study arrest secondary to adverse events coupled to busulfan and sirolimus e.g. sever 
sinusoidal obstructive syndrome, portal vein thrombosis altered mental status and risk for 
poor wound healing, the degree of acute-GvHD, however was not inferior to calcineurin 
inhibitors (Johnston et al., 2012; Schleuning et al., 2009).   
1.12.6 Unrelated transplantations and T-cell depletion 
The increased relapse in recipients of T-cell depleted grafts made before 1988 are a major 
evidence of the graft-versus-leukemia effect mediated by the depleted cells in the graft 
(Marmont et al., 1991). The GvHD-prophylaxis need to be more intense with a stronger 
barrier in unrelated donor-recipient pairs, -and with donor-recipient HLA-mismatches. The 
use of T-cell depletion weakens the barrier further in unrelated transplants where a high risk 
of fatal acute-GvHD is present, which may be especially important in adults (Remberger et 
al., 1998). 
T-cell depletion may be made ex-vivo by positive selection of the graft by CD34+ antibodies, 
or by negative selection by CD3+ cell antibodies. Anti-thymocyte globulines (ATG) from 
animals sensitized to the human leukocytoid cells given during the preparative regimen, but 
avoiding the transplantation day have become the established method of in-vivo T-cell 
depletion (Busca & Aversa, 2017). The ATG stays in the recipient and elicit in-vivo T-cell 
depletion on the graft. These polyclonal anti-thymocyte globulines have an affinity to a range 
of different molecules on cell surfaces , among them CD4+ and CD11a+ depending on how 
specific the selection of the leukocytoid cells that are infused into the animal which are to 
develop adoptive immunity against the human cells are. All of the anti-thymocyte globulines 
have a strong anti-CD3 effect (Bourdage & Hamlin, 1995; Fang, Fehse, Engel, Zander, & 
Kroger, 2005).  
1.12.7 Donor lymphocyte infusions 
If the graft fails to engraft, or the leukemia is coming back, the patient has to be saved. Donor 
cells can be obtained in the same way as when obtaining a graft for transplantation, by 
marrow aspiration or by mobilization from the peripheral blood by G-CSF and harvesting by 
leukapheresis (Remberger et al., 1998). Donor Lymphocyte Infusion is an adoptive 
immunotherapy to increase the GvL effect (Kolb et al., 1990), which can be used to stop a 
fulminant relapse when molecular- or cytogenic residual disease is detected (Sairafi et al., 
2010). The GvL after DLI has been monitored by cytogenic markers in CML and when the 
leukemia can be detected in the blood the GvL has been found to come two weeks earlier 
than GvHD (Hari, Logan, & Drobyski, 2004). 
1.13 SUPPORTIVE THERAPY AND HOME CARE  
The supportive therapy managed by the staff at the transplant center is the key of transplant 
success. In addition to the transplant protocol described, there is a need of professional and 
experienced care during the pancytopenic phase. In addition to the frequent blood sampling 
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and the administration of the graft-versus-host prophylaxis and the prophylactic antibiotics 
used during the pancytopenic phase, the need for discussion with and advice from 
experienced staff is imminent. The place for care may have an impact on the outcome of 
transplantation, in a single center study and a long-term follow up, home-care has been 
superior to care at the ward with protected environment, with less incidence of acute-GvHD 
(Svahn et al., 2002).  
1.14 THE FIRST AND SECOND LINE TREATMENTS OF ACUTE-GVHD 
1.14.1 Corticosteroids in the treatment of acute GvHD  
The most up-to date recommendations of acute-GvHD treatment are the first and second-line 
treatment recommendations of the American society for Blood and Bone Marrow 
Transplantation from 2012. There is a broad consensus on a first line treatment for acute-
GvHD grade≥II with prednisolone 2 mg/kg/day or methylprednisolone 2.0 – 2.5 mg/kg/day, 
with a complete response rate of 40-50% (Deeg, 2007; Martin et al., 2012).  
1.14.2 Second line therapy 
Photochemotherapy has so far been offered for patients suffering predominantly acute-GvHD 
of the skin. There is a lack of prospective randomized studies on second line treatment. 
However, most second line treatments rely on retrospective studies, and there is no consensus 
on the best second line treatment. The results obtained from these retrospective studies of 
second-line treatments for acute GvHD suggest several treatment strategies including 
methotrexate, MMF, photochemotherapy, narrowband ultraviolet B, Extracorporeal 
photochemotherapy, daclizumab, alemtuzumab, horse ATG, etanercept, infliximab, horse 
ATG+etanercept, daclizamab+infliximab, daclizamab+infliximab+horse ATG and sirolimus 
(Deeg, 2007; Feldstein, Bolanos-Meade, Anders, & Abuav, 2011; Furlong et al., 2002; 
Martin et al., 2012; Wiesmann et al., 1999). 
1.14.3 Phase II & III studies 
Phase II studies has been carried out based on several treatments including basiliximab, 
daclizumab, inolimomab, denileukin diftitox, alemtuzumab, horse ATG, mesenchymal cells 
and the combination of daclizumab and etanercept. Phase III studies have been carried out 
using horse ATG. At this time-point, no treatment can be determined as superior or inferior to 
any other. The response rate and the complete response rate at day 28 of treatment, as well as 
the 6-months survival, are identified as important end-points for future research design of 
treatment studies of acute-GvHD (Martin et al., 2012). 
1.14.4 Etanercept combinations 
Two prospective studies of severe steroid resistant acute-GvHD with combinations with 
etanercept have been carried out and were reported 2015 and 2017.  
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In the first study, the majority had gastrointestinal acute-GvHD stage 3-4 (n=19) after ASCT 
and a few (n=5) after donor-lymphocyte- infusion. These patients were treated with a 
combination of etanercept (anti-tumor necrosis factor-alpha) and inolimab (anti-IL-2 receptor 
alpha) with a complete response rate of 4/21 at day 28 and a two years survival of 10% (van 
Groningen et al., 2016).  
In the second study etanrecept and basiliximab (anti-IL-2 receptor alpha) were given to a 
patient group where the majority experienced acute-GvHD of the skin and a minority had 
visceral acute-GvHD. In this multicenter study of 65 patients, the majority had acute 
leukemia and was treated with myeloablative conditioning. These patients developed grade 
III-IV severe acute-GvHD. Treatment using a combination of basiliximab and etanercept 
showed a higher complete response (75.4% vs. 29.6%, p<0.001), compared to a retrospective 
cohort identified from the database of the first affiliated hospital of Zhejiang University 
School of Medicine using all patients (n=27) with severe SR-acute-GvHD before 2009. The 
patients in the control group received some other second-line salvage treatment including 
high-dose steroid (2-5 mg/kg) (n=2), FK506 (n=7), CD3 antibody (OKT3)(n=5), CD25 
antibody (daclizumab) alone (n=9), or plasmapheresis (n=6) at the discretion of the 
physicians. The combination etanercept and basiliximab resulted in a 2-year relapse incidence 
of 19% and a non-relapse mortality of 24.9%, and a one year survival of 62.1% and a two 
year survival of 54.7%, compared to the previously best reported CR (69%) and 6-month 
survival of 56% of a retrospective report of predominantly steroid resistant visceral acute-
GvHD of the combination of horse ATG and etanercept (Kennedy et al., 2006; Tan et al., 
2017). 
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1.15 THE DEVELOPMENT OF PHOTOCHEMOTHERAPY 
1.15.1 First generation:  
Phototherapy and photochemotherapy was firstly used 3400 years ago and is the oldest 
therapy described in human history. Psoralens are tricyclic furanocoumarins found in the 
common fig, celery, parsley, west Indian satinwood and in citrus fruits  (M. A. Pathak, 
Daniels, & Fitzpatrick, 1962). The compounds are known to intercalate and form crosslinking 
with the pyrimidines in the DNA strands after they have been photosensitized by sunlight 
(Figure 7). This concept provides an opportunity for a group of therapies that is the oldest 
known therapies still in use. Psoralens were administered topically, in the absence of light, 
and when sufficient amount of photosensitizer were taken up by tissue, exposing the patient 
to sunlight will then activates the photosensitizer. This therapy has been recommended to 
cure of the T-cell mediated cutaneous leprosy and the T-cell mediated Vitiligo and can be 
traced to the sacred book of Atharva Veda (Bloomfield, M.: Sacred Books of the East; 
Hymns of Atharva-Veda, Vol. XLII, Claredon Press, Oxford, 1897).  
“Born by night art thou, 
O plant, dark, black, sable do thou, 
that art rich in color, stain 
this leprosy and the gray spots.” 
1.15.2 The second generation: 
Noble Laurate Niels Finsen (1903) introduced the second generation of phototherapy when 
he created a lamp that could eradicate cutaneous tuberculosis far more efficient than any 
other previous therapy. This therapy was the basis for the eradication of cutaneous 
Tuberculosis in Scandinavia. 
“In recognition of his contribution to the treatment of diseases, 
especially lupus vulgaris, with concentrated light radiation, whereby he has opened 
a new avenue for medical science”, “The Nobel prize in Physiology or Medicine 1903” 
1.15.3 The third generation: 
The construction of fluorescent lamp systems that can provide an even exposure of the total 
body surface e.g. provide an even exposure over 213 by 122 centimeter where it emits high-
intensity radiation between 320 and 390 nm with a peak emission of 365 nm, together with 
the oral pharmaceutic formulation of 8-methoxysalen opened up the next generation of 
photochemotherapy, which was a revolutionary cure for psoriasis (Parrish, Fitzpatrick, 
Tanenbaum, & Pathak, 1974). 
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Figure 7. DNA Crosslinking agents 
 
 
Examples of DNA Crosslinking Agents. The chemical structure of the indicated agent is 
shown in the top row. The bottom row depicts the nature of the ICL. (i) Nitrogen mustards 
form a 1,3 ICL between the N7-positions of two G residues on opposite strands within a 5'-
d(GNC) sequence. Mitomycin C (MMC; ii) and cisplatin (iii) generate ICLs between 
juxtapose Gs of 5'-d(GC). (iv) [SC1]Psoralen can produce ICLs between the T residues of 5'-
d(TA) complementary sequences upon exposure to UVA. The frequency of ICLs for cisplatin 
is around 5–10% of the total adducts, about 5% for nitrogen mustards, less than 10% for 
MMC, and 20–30% for psoralen. Reprinted from Trends in Biochemical Sciences, Vol. 35, 
David M. Wilson, Michael M. Seidman, A novel link to base excision repair? pp. 247-252. 
Copyright (2010), with permission from Elsevier  
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1.16 PHOTOCHEMOTHERAPY IN THE TREATMENT OF CUTANEOUS ACUTE-
GVHD 
1.16.1 The clinical experience of photochemotherapy on cutaneous acute-
GvHD 
The clinical experience of the effects of treatment of cutaneous acute-GvHD by 
photochemotherapy, has been based on measuring the effects in the skin. In 1986, Atkinson 
K. reported the results of the treatment of three patients, who received HLA-identical sibling 
transplantation for severe-aplastic anemia (SAA), CML and ALL respectively, with  
photochemotherapy, at a dose of 0.75-1.25 J daily for four days per week after the 
administration of 0.6 mg/kg (oral 8-methoxypsoralen) orally. The conditioning regimen was 
cyclophosphamide 50 mg/kg for x 4 four times for SAA, and cyclophosphamide 60 mg/kg x2 
+ fractionated TBI 12 gray for the malignancies. Graft-versus-host prophylaxis was 
cyclosporine and in the last case addition of T-cell depletion, subsequently, the last patient 
was treated for an acute-cutaneous GvHD stage IV. The patient with ALL started at day 73 
post-transplant after a treatment with methylprednisolone since day 11, and antithymocyte 
globulines repeatedly  since day 40, followed by cyclophosphamide 200 mg/day during two 
weeks and during the period of ten treatments of photochemotherapy, the skin scaling, 
edema, erythema and petechial decreased in intensity. The treatment had however to stop, 
since the patient deteriorated in septicemia and died within 100 days post-transplantation of 
staphylococcal infection. 
In 1990, Eppinger T. reported the results of the treatment of 11 patients with cutaneous acute 
GvHD. The 8-methoxypsoralen photosensitized the skin after oral administration, two hours 
before irradiation with ultraviolet type A. Four patients with cutaneous acute-GvHD were 
treated, two with HLA-identical donors who received cyclosporine as GvHD-prophylaxis, 
and two one antigen mismatched donors who received methotrexate and campath-1 antibody 
in addition. The conditioning was cyclophosphamide 4x50 mg/kg and etoposide (50 
mg/kg/bw) or busulfan (4x4 mg/kg/bw) respectively for the matched recipients, and 
cyclophosphamide 2x60mg/kg/bw, TBI 12 gray for the recipients who received antigen 
mismatched grafts, where the last one also received etoposide (30mg/kg/bw). The matched 
recipients started photochemotherapy at 70 days and 72 days post-transplant respectively and 
received 23 and 14 treatments with an accumulated dose of 67 and 31.5 J/cm2, after which 
they went into complete remission. The patients who received antigen-mismatch marrow and 
was treated with Campath-1 (an antibody against CD52 on the mature lymphocytes, the 
monocytes and the dendritic cells) after transplantation showed only had a partial remission 
and survived only 45 and 250 days, respectively. 
In a study of acute- and chronic GvHD, from 1995, Aubin F. et al. reported the results of 
photochemotherapy of four patients with cutaneous acute-GvHD after HLA-identical sibling 
grafts. The first three patients with ALL (12 y.o.), AML (6 y.o.) and CML (54 y.o.) received 
a conditioning regimen of TBI in combination with either cytarabin/ and melphalan for the 
children, or cyclophosphamide for the adult, before they started a graft-versus-host 
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prophylaxis of cyclosporine and methotrexate. The cutaneous acute-GvHD was stage III-IV 
and had an onset at day 18 (range 15-30). The children received photochemotherapy after a 
line of treatments beginning with corticosteroids, followed by cyclosporine and anti-CD5 & 
anti-CD8; corticosteroids and additional cyclosporine and thalidomide or anti-CD25 and 
finally anti-CD25 or anti-TNF. The adult received photochemotherapy as a second-line 
treatment in addition to initiated corticosteroids and cyclosporine as first line treatment. The 
start of photochemotherapy was at day median 54 (range 25-66) of acute cutaneous GvHD. 
These three patients had to a complete response. At seven months the 6 y.o. and the 54 y.o. 
developed chronic GvHD which responded to therapy. The survival was at least median 42 
months (52 – 73) after transplantation. The fourth patient, a 20 y.o. female, who was treated 
for cutaneous acute-GvHD which started at day 13 after a GvHD-prophylaxis of 
methotrexate and cyclosporine, had received busulfan, cytarabin and melphalan for ALL. She 
developed a stage III cutaneous acute-GvHD and was treated with corticosteroids and 
+cyclosporine and anti-CD25, thalidomide and finally addition of photochemotherapy at day 
98. The cutaneous GvHD did not repond to the therapy and the patient was only able to 
receive three treatments of photochemotherapy before she died in interstitial pneumonia four 
months after transplantation. The treatments were given two hours after photosensitization 
with 8-methozysalen with a starting dose of 0.5 J/cm2 three times a week. The three survivors 
accumulated median 23 (11-25) treatments with an accumulated dose of 85 (30-90) J/cm2 
(Aubin et al., 1995).   
A larger other study came was published in 1999 by Wiessman A. et al. who reported their 
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in combination with the myeloablative addition of busulfan (16 mg/kg; n=13) and 
fractionated TBI (12 Gy; n=7). Thirteen were transplanted from a related donor and seven 
were transplanted with a graft from an unrelated donor. The graft-versus-host prophylaxis 
was cyclosporine with a conventional basic treatment of methotrexate. Five patients received 
anti-thymocyte globuline. The lowest degree of acute-cutaneous GvHD included in the study 
was stage II, i.e. >25% of the TBSA covered by erythema, why it is difficult to determine 
four how long the skin symptoms had been present until the prednisolone therapy was 
initiated. The initial therapy of acute-GvHD was prednisolone 2mg/kg and if the cutaneous 
acute GvHD progressed after three days photochemotherapy was started. The authors used a 
unique scoring system for skin-disease severity, intensity of erythema x % body surface area 
+ size of bullae x % body surface area affected. The combined prednisolone and early 
photochemotherapy led to a progression of cutaneous acute-GvHD in four cases, four had 
relapse of malignancy, and none of these patients had concomitant visceral disease. Only two 
patients with visceral disease resolved the disease. Overall 55% (n=11) survived, and the 
overall 50% reduction of prednisolone was 35 days (5-133) and the response rate for acute-
GvHD of the skin was 92% (Wiesmann et al., 1999). 
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In 2002, the by far most numerous experience of cutaneous acute-GvHD treated by 
photochemotherapy was published by the Seattle group at Sloan Kettering. The study 
photochemotherapy was initiated at median day 30 (range 11 – 79), and a high ratio of the 
patients, 92% of the evaluable 95 developed chronic GvHD, but no relapse data was reported. 
The Kaplan and Meier estimated survival at five years from the start of photochemotherapy 
as 43%. This study had a majority of unrelated donors 74/103 vs. 29/103 related donors, with 
a majority who received a cyclosporine plus methotrexate as acute GvHD prophylaxis. The 
mean number of treatments was 16 (range, 1-78), with a mean cumulative exposure of 41 
J/cm2. The majority had stage III skin disease, with a cutaneous rash that covered > 50% of 
the body surface area. In this study only patients with hepatic or gastrointestinal disease were 
treated if the symptoms seemed mild or were resolving (Furlong T. 2002). In both these 
studies the majority tolerated photochemotherapy well, and in the Furlong study a majority 
went through a six week therapy (Furlong et al., 2002; Wiesmann et al., 1999). 
1.17 CUTANEOUS EFFECTS OF PHOTOCHEMOTHERAPY  
1.17.1 Suppression of DTH and carcinogenesis 
The delayed type hypersensitivity reaction in the skin of patients treated by 
photochemotherapy is known to decrease (Moss, Friedmann, & Shuster, 1980). This effect 
differs from the effect of ultraviolet light type B, as photochemotherapy suppresses the 
delayed type hypersensitivity reaction independently of the erythematous reaction of the skin 
in allergic patients (Kalimo, Koulu, & Jansen, 1983).   
The modern photochemotherapy was established as a treatment to induce remission in 
psoriasis before the era of monoclonal antibodies (Parrish et al., 1974). Extensive use (1000 
J/cm2) can however cause skin cancer, a reason for why the therapy should be used in 
moderate doses. Photochemotherapy has three important co-carcinogens, two where cases of 
cancer have been described in patients with accumulated doses between (51 – 895 J/cm2), e.g. 
ionizing radiation therapy and arsenic exposure, while the third risk factor is skin cancer. The 
lowest reported accumulated dose is from a single patient who had four years of superficial 
X-ray therapy between 1942 - 1946 and developed squamous cell carcinoma in 1982 after a 
treatment of 51 J/cm2 of photochemotherapy during 1.5 years (Studniberg & Weller, 1993; 
Torinuki & Tagami, 1988). 
1.17.2 Downregulation of costimulation with HLA-class II at the surface 
Photochemotherapy further stands out from UVB by the histopathological response in 
psoriatic patients. In a comparative study of punch biopsies of 4 mm skin, the majority from 
the glutea, before and after response to cyclosporine, UVB or photochemotherapy, 
photochemotherapy was reported to more significantly decrease the numbers of CD1a+ cells 
in the epidermis and in the dermis in psoriatic patient responding to treatment. In the 
epidermis however, the photochemotherapy does not downregulate the HLA class-II 
molecules, but do downregulate the co-stimulatory molecule CD86. Cyclosporine alone 
keeps the CD1a+ cells in the epidermis and the CD4+ and the CD1a+ cells in the dermis. 
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UVB keeps the CD1a+ cells in the epidermis together with CD68+ expression. All treatments 
downregulate the CD8+ population in psoriatic skin (Erkin G. 2007) Photochemotherapy has 
effects on cell-surface molecules associated with adhesion and costimulation on several cell-
types in the psoriatic skin (Figure 8) (Stern, 2007).  
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Figure 8. The effects of photochemotherapy on the psoriatic skin 
 
Reproduced with permission from Stern R. 2007: Psoralen and Ultraviolet A Light therapy 
for psoriasis; New England Journal of Medicine, Vol. 357 pp. 682-90 Copyright 
Massachusetts Medical Society 
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1.17.3 Photochemotherapy and tissue-antigen presenting capacity 
The in-vitro antigen stimulatory capacity of the epidermal skin seems to decrease after 
treatment of 8-MOP and UVA. In study of predominantly patients with psoriasis who 
underwent routine photochemotherapy, but where the lower left arm was shielded from 
UVA, the difference in cell populations by cell surface markers were compared within the 
same individual after harvesting of epidermal sheets from both arms by the suction-blister 
method. The harvested cells were suspended in an epidermal solution and their examined by 
fluorescence activated cell sorter (FACS) and their allo-stimulatory capacity was evaluated. 
The overall number of HLA DR+ CD1a+ Langerhan cells in the epidermis decreased 
dependent on the dose of photochemotherapy received, and at higher doses of a median of 40 
J/cm2 (range 22.8 – 59.7) the decreased number remained down regulated up to ten days, 
while at a low dose 10.7 J/cm2 the repopulation was almost total at eight days (89%). The 
autologous antigen presenting capacity was diminished after concavalin and tetanus toxin 
provocation, while the capacity to induce an allogeneic response was decreased in epidermal-
lymphocyte reactions, and in unsorted epidermal cell mixed lymphocyte reactions, but not 
after the aliquots of epidermal sheets from the exposed and UVA-unexposed forearms had 
been enriched by FACS to contain the same number of HLA-DR+ CD1a+ cells (Ashworth, 
Kahan, & Breathnach, 1989). 
1.17.4 The effect on regulatory T-cells 
The regulatory T-cells within the CD4+CD25+ cell population were found by Sakaguchi S. et 
al. (Sakaguchi, Sakaguchi, Asano, Itoh, & Toda, 1995) who transplanted CD25 depleted and 
CD25 repleted CD4 cells to the athymic nu/nu mice, which lacks their own production of T-
cells. After transplantation of CD25- depleted cells, all athymic mice developed autoimmune 
diseases, including GvHD. Furthermore, the nu/nu repleted CD4CD25+ had a better 
tolerance towards allogeneic skin grafts, than the CD4CD25- or the CD8+ cell transplants 
(Sakaguchi et al., 1995). The CD4+CD25+ population has been further investigated, and the 
identification of the transcription factor FoxP3 more precise defined a cell population within 
the CD4+CD25+ with a high cytokine production, but with an ability to suppress other T-
cells upon cell contact (Hori, Nomura, & Sakaguchi, 2003). The human FoxP3+ population 
can be separated in at least three populations, among these resting cells 
(CD4+CD25+RA+Foxp3low) and activated T-regulatory cells (CD4+CD25+RA-
FoxP3high), however the FoxP3 population is dynamic and may be diverted into a Th17 
population which aggravates an immune response (Miyara et al., 2009). 
In classic murine studies, high-dose topical photochemotherapy and subsequent provocation 
with haptens known to induce DTH has been found to induce suppressor cells in the spleen 
and in the local lymphnodes, which attenuate the DTH with antigen specificity in syngeneic 
recipients (Kripke, Morison, & Parrish, 1983; Wolf et al., 2006). Singh et al. could in 
repeated studies of the K5.hTGF-beta 1 transgenic mice, which display a poriatic skin type, 
show an increase of the regulatory T-cells after repeated low dose photochemotherapy (0.25 
J-0.50 J/Cm2 twice a week four weeks in a row with a good treatment response (Singh et al., 
 
 59 
1.17.3 Photochemotherapy and tissue-antigen presenting capacity 
The in-vitro antigen stimulatory capacity of the epidermal skin seems to decrease after 
treatment of 8-MOP and UVA. In study of predominantly patients with psoriasis who 
underwent routine photochemotherapy, but where the lower left arm was shielded from 
UVA, the difference in cell populations by cell surface markers were compared within the 
same individual after harvesting of epidermal sheets from both arms by the suction-blister 
method. The harvested cells were suspended in an epidermal solution and their examined by 
fluorescence activated cell sorter (FACS) and their allo-stimulatory capacity was evaluated. 
The overall number of HLA DR+ CD1a+ Langerhan cells in the epidermis decreased 
dependent on the dose of photochemotherapy received, and at higher doses of a median of 40 
J/cm2 (range 22.8 – 59.7) the decreased number remained down regulated up to ten days, 
while at a low dose 10.7 J/cm2 the repopulation was almost total at eight days (89%). The 
autologous antigen presenting capacity was diminished after concavalin and tetanus toxin 
provocation, while the capacity to induce an allogeneic response was decreased in epidermal-
lymphocyte reactions, and in unsorted epidermal cell mixed lymphocyte reactions, but not 
after the aliquots of epidermal sheets from the exposed and UVA-unexposed forearms had 
been enriched by FACS to contain the same number of HLA-DR+ CD1a+ cells (Ashworth, 
Kahan, & Breathnach, 1989). 
1.17.4 The effect on regulatory T-cells 
The regulatory T-cells within the CD4+CD25+ cell population were found by Sakaguchi S. et 
al. (Sakaguchi, Sakaguchi, Asano, Itoh, & Toda, 1995) who transplanted CD25 depleted and 
CD25 repleted CD4 cells to the athymic nu/nu mice, which lacks their own production of T-
cells. After transplantation of CD25- depleted cells, all athymic mice developed autoimmune 
diseases, including GvHD. Furthermore, the nu/nu repleted CD4CD25+ had a better 
tolerance towards allogeneic skin grafts, than the CD4CD25- or the CD8+ cell transplants 
(Sakaguchi et al., 1995). The CD4+CD25+ population has been further investigated, and the 
identification of the transcription factor FoxP3 more precise defined a cell population within 
the CD4+CD25+ with a high cytokine production, but with an ability to suppress other T-
cells upon cell contact (Hori, Nomura, & Sakaguchi, 2003). The human FoxP3+ population 
can be separated in at least three populations, among these resting cells 
(CD4+CD25+RA+Foxp3low) and activated T-regulatory cells (CD4+CD25+RA-
FoxP3high), however the FoxP3 population is dynamic and may be diverted into a Th17 
population which aggravates an immune response (Miyara et al., 2009). 
In classic murine studies, high-dose topical photochemotherapy and subsequent provocation 
with haptens known to induce DTH has been found to induce suppressor cells in the spleen 
and in the local lymphnodes, which attenuate the DTH with antigen specificity in syngeneic 
recipients (Kripke, Morison, & Parrish, 1983; Wolf et al., 2006). Singh et al. could in 
repeated studies of the K5.hTGF-beta 1 transgenic mice, which display a poriatic skin type, 
show an increase of the regulatory T-cells after repeated low dose photochemotherapy (0.25 
J-0.50 J/Cm2 twice a week four weeks in a row with a good treatment response (Singh et al., 
 60 
2010). In human, the regulatory cells in the CD4+ cell population, (CD25+FoxP3+/CD4+), in 
peripheral blood  increase with bath-PUVA treatment and are associated with with a 
treatment response of psoriasis after an accumulated dose of 31.2 J/Cm2 (range 6-54) (Saito 
C. 2009). The regulatory T-cell compartment can be divided into different subgroups which 
are suggested to be correlated to their suppressive function. Within the regulatory T-cell 
group (CD4+CD25+), the cell surface markers CD45RA and FoxP3 can be used to identify 
cells that are activated (CD4+CD25+CD45RA-FoxP3high) and are suggested to have the 
most suppressive function (Miyara et al., 2009). The Bath-PUVA has been studied 
extensively with regards to the induction of regulatory-T-cells and their coupling to the 
remission of psoriasis, where a shift from circulating Th17 cells to circulating 
CD4+CD25+Foxp3+ cells have been seen by FACS (Furuhashi T. 2013). In a study of whole 
blood on psoriatic patients (n=15) with controls (n=11), Bath-PUVA changed the balance 
between resting T-regs and activated T-regs in patients, while the opposite happens in the 
healthy controls, which turn from activated to resting T-regs. Furthermore, Bath-PUVA has a 
maximum induction dose of 15 treatments whereafter the balance in peripheral blood is partly 
reversed. The subgroup of regulatory T-cells were reported to be evoked most easily in 
psortiatic patients that are juvenile to Bath-PUVA (Kubo et al., 2017).  
In Bath-PUVA, Bath-water containing 8-methoxypsoralen which photosensitizes the skin 
after which ultraviolet type A irradiation is administered to the skin of the patient, which is 
considered an atoxic and inexpensive treatment. The remission period of psoriasis has been 
found to be longer with bath-PUVA (Photochemotherapy after topical administration of 
psoralen), than with Narrowband UVB (Brazzelli et al., 2008), the same is known to be true 
for photochemotherapy of the skin (Stern, 2007). Photochemotherapy reduces the IL-6, IL-8. 
IL-2, Interferon-gamma, and Tnf-alpha in skin biopsies from psoriatic patients, whereas IL-
10 was not affected (Olaniran et al., 1996). 
1.17.5 Photochemotherapy and Vitamin D 
Photochemotherapy elevates the levels of 25-OH vitamin D (Shuster, Chadwick, Moss, & 
Marks, 1981). Ultraviolet light initially produces 1,25-Dihydroxyvitamin D3 that in murine 
models induce retinoic acid production in professional antigen presenting cells and the 
induction of FoxP3 (Kang et al., 2012; Sato et al., 2013). The retinoic acid producing APCs 
in the skin draining lymph nodes are derived from the dermis (Guilliams et al., 2010) and 
stimulate a gut-homing, IL-10 producing population of regulatory T-cells (Bakdash, 
Vogelpoel, van Capel, Kapsenberg, & de Jong, 2015; Iwata et al., 2004). 
Hypothethically, the effects of photochemotherapy through the induction of Vitamin D may 
attenuate lung disease, as increased levels of 1,25-Dihydroxyvitamin D3 in the skin induces 
regulatory cells in the local lymph nodes with suppressive effects on lung responsiveness in a 
hypersensitivity murine model (Gorman, Judge, Burchell, Turner, & Hart, 2010). Low levels 
of vitamin D have also been reported in children and adults with airway hypersensitivity and 
impaired lung function (Beyhan-Sagmen, Baykan, Balcan, & Ceyhan, 2017; Maatta et al., 
2017). 
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1.17.6 Photochemotherapy in immunocompromised conditions 
The immunity against viral infections seems not to be inhibited by photochemotherapy. In 
patients with advance stage HIV and psoriasis (n=2), prurigo (n=1) or folliculitis (n=3), 
cutaneous photochemotherapy does not seem to increase the viral load or have any effect on 
the CD4+ count in the doses of 0.5-1 J/cm2 (Horn, Morison, Farzadegan, Zmudzka, & Beer, 
1994). 
1.17.7 T-regulatory cells and remaining leukemia 
In addition to the research on photochemotherapy, two aspects have to be taken into 
consideration when post-transplantation setting is discussed. Firstly, the regulatory T-cell 
compartment is modified by immunosuppressive drugs (Daniel, Trojan, & Opelz, 2016), 
secondly, T-regs seem to mediate a part of their regulatory function through cytotoxicity, 
since their function in an experimental model is coupled to granzyme A (Velaga et al., 2015). 
The regulatory capacity thus may eradicate cells that elicit the acute-GvHD, but they may 
also possibly target cells within the leukemia, and thus exercise GvL. 
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1.18 TRANSPLANTATION OF LEUKEMIA AND THE CLINICAL OUTCOME  
1.18.1 Acute Lymphoblastic Leukemia (ALL)  
Patients with acute Lymphoblastic Leukemia (ALL) in first remission have a potent graft-
versus-leukemia effect if they are transplanted with a related donor. Relapsed leukemia, as 
well as leukemia with remaining minimal residual disease positivity as well as Philadelphia 
chromosome positivity or Philadelphia like positivity and T-cell, are at high-risk and should 
be offered allogeneic stem cell transplantation (Inbar et al., 2017).   
1.18.2 Acute Myeloid leukemia (AML) 
In Acute Myeloid leukemia (AML) allogeneic stem cell transplantation with HLA-identical 
sibling donor can offer a curative long-term leukemia free survival in patients in primary 
complete remission, and in some patients in relapse. The increased availability of unrelated 
donors can offer the opportunity to find a KIR-mismatched donor if no sibling donors is at 
hand (Gyurkocza et al., 2017). 
1.18.3 Chronic myeloid leukemia (CML) 
The incidence of chronic myeloid leukemia is slightly higher for females (1.2-1.7 times), and 
with an onset at 57-60 years of age, the prevalence is increasing from 10-12/100.000 due to 
improved therapeutic options (Höglund M 2015). Allogeneic stem cell transplantation 
remains a curative alternative forCML, as a primary alternative or when chimeric-antigen T-
cell therapy fails and tyrosine inhibitor resistance develops (Patel, Wilds, & Deininger, 2017). 
1.18.4 The diagnosis of haematological Remission & Relapse 
In morphological examination, clinical remission is considered when less than 5% blast cells 
were found among 200 nucleated cells. Relapse is diagnosed with bone-marrow (BM) 
aspirates from the iliac crest in local anesthesia and comfort sedation (Diazepam or 
Midazolam). A BM aspirate is acquired at clinical signs of relapse or at 3, 6 or 12 months 
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BM aspirates were considered a relapse. Further subtyping is made according to the 
subtyping of the blasts within each disease, and classification within diagnostic criterias e.g. 
French-American-British criteria for AML with assorted genetic abnormalities (FAB) (Figure 
9). The classification of the malignancy that made the transplantation necessary is at this 
stage already known. The presence of extramedullary leukemic cells was considered as an 
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Minimal residual disease & Molecular relapse are diagnosed by reverse transcripts of 
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Figure 9. Cytologic Findings in Bone Marrow Specimens and Peripheral-Blood Smears from 
a Patient with Subtype M2 AML and the t(8;21)(q22;q22) translocation (FAB); Leukemic 
blasts. 
 
In Panel A, a bone marrow specimen contains medium-sized blasts, cytoplasm with no 
granulation, and nucleoli that are sometimes clearly visible (May–Grünwald–Giemsa, 
¬1600). Panel B shows a bone marrow specimen with myeloperoxidase-stained blasts 
(¬1600). Panel C shows a leukemic blast with an Auer body (arrow) (May–Grünwald–
Giemsa, ¬1600). Panel D shows a blast stained with May–Grünwald–Giemsa in a peripheral-
blood smear (¬1000). Panel E shows the results of fluorescence in situ hybridization of the 
cell shown in Panel D with probes specific for the breakpoint regions of chromosome 8(q22) 
(isolated green spot) and chromosome 21(q22) (isolated magenta spot) (¬1000). The arrow 
indicates the chromosomal fusion (clustered green and magenta spots). 
 
Reproduced with permission from Bob Lowenberg, M.D., James R. Downing, M.D., and 
Alan Burnett, M.D. 1999: Acute Myeloid Leukemia; The New England Journal of Medicine, 
Vol. 341 pp. 1051-1062 Copyright Massachusetts Medical Society 
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2 DISCUSSION OF THE LITERATURE 
Leukemia has been a burden for mankind throughout history, and although the field of 
allogeneic hematopoietic transplantation has branched with haploidentical transplantations 
(Luznik et al., 2008) and reduced intensity conditioning (Giralt et al., 1997). Still the 
myeloablative transplantation with matched unrelated donors remains an established therapy 
with competitive results within ALL, AML and CML (Gyurkocza et al., 2017; Inbar et al., 
2017; Patel et al., 2017). 
The key question to increase long-term-disease free survival is to decrease the treatment-
failure and the two main reasons are recurrence of cancer and GvHD (Gyurkocza et al., 2017; 
Nassereddine et al., 2017). These two outcomes are found to be associated in several large 
register studies (Gratwohl et al., 1995; Horowitz et al., 1990; Ringden et al., 1996). The time-
point for the initiation of the GvL in relation to the GvHD reaction after transplantation has 
however not been clarified. Despite that animal studies have suggested that the cell mediated 
immunity that leads to GvL and GvHD takes a week to be ready to be promoted further 
(Bortin et al., 1973; Saltzstein et al., 1972) and GvL has been shown to be present two weeks 
before acute-GvHD after DLI against CML, the chronic GvHD is still by many regarded as 
the crucial event for disease free survival (Horowitz et al., 1990). This view is however 
contested by the landmark analysis of the IBMTR patients transplanted in the period 1997 – 
2005 (D. Weisdorf et al., 2012). However, two studies identified early cutaneous acute-
GvHD as important for the GvL in CML (Gratwohl et al., 1995; Ringden et al., 1996). In 
addition to this comes the experience from AML in first untreated relapse, where acute 
GvHD grade II-III is identified as a key factor for a successful eradication of cancer and 
survival (Appelbaum & Pearce, 2006; Gyurkocza et al., 2017), The temporality of the GvL 
effect thus may be shifted from chronic GvHD to be evoked by an acute-GvHD which 
extends into or is followed by a chronic GvHD.  
The organ staging of the GvHD organ involvement of the skin, the liver and the gut 
established by Glucksberg et al. has been stable for over four decades (Glucksberg et al., 
1974). When the IBMTR adjusted the overall grading to the outcome data after the first two 
decades of transplantation, the staging of gut, liver and cutaneous acute-GvHD was not 
changed (Rowlings et al., 1997). The postmortem report of Beschorner et al. postulated a 
direct correlation between acute-GvHD and onset of deadly pulmonary disease. The autopsy 
findings showed an association between bronchopneumonia or extensive acute bronchitis and 
acute-GvHD grade II-IV (Beschorner et al., 1978). Subsequently, the high incidence of 
GvHD and IPS in myeloablative transplantation leads to the development of RIC (Giralt et 
al., 1997; Ringden et al., 1993). There is a shift within the view on lung disease after 
transplantation, from being regarded as idiopathic, towards being viewed partly as secondary 
to the immune response evoked by the graft. Lung acute-GvHD is only established within the 
experimental animal models, where a gut-liver-lung paradigm is predominant. The early lung 
disease after transplantation remains fatal with a reported mortality of 96% in patients 
needing mechanical ventilation (Fukuda et al., 2003; Panoskaltsis-Mortari et al., 2011). 
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Specific reports on the histopathological pattern of lung biopsies in patients with cutaneous 
acute-GvHD are missing, but after the first 100 days, the fourth and fifth month after 
transplantation lymphocyte infiltration is general, but beside that, the histological picture in 
the lung is somewhat diverse, and cathegorized as BOOP, BO, ALI, OB, OP, which however 
all fits in within the IPS (Panoskaltsis-Mortari et al., 2011; Xu et al., 2013; Yousem, 
1995).These reports do not have the numbers to support or dismiss a skin-lung connection 
after transplantation and the albeit minor histopathological diversity the picture in the lung 
reported is a picture of lymphocyte infiltration which is similar to what is seen in the skin 
during cutaneous acute-GvHD. Cutaneous acute-GvHD and biopsy proved upper 
gastrointestinal GvHD are associated, and both the upper GI and the skin, as well as the lung, 
may produce elafin, thus if they share the same constitutive expression and the same response 
to inflammation, they may hypothethically by analogy also be the shared target area for 
acute-GvHD. 
The transplantation demands a conditioning regimen where either TBI or Bu can be used. 
Ionizing irradiation and photochemotherapy are known cocarcinogens (Studniberg & Weller, 
1993; Torinuki & Tagami, 1988). Thus, a possibly stronger effect on cells can be expected by 
photochemotherapy in the myeloablative TBI group. These groups are therefore analyzed 
separately. The T-cell depletion in the majority of patients are given as the established in-vivo 
depletion by ATG ought also to be analysed either as a group or as a predictor, as it is well 
known that ATG decreases both DTH, but also cell-mediated immunity (Busca & Aversa, 
2017; Katsura, Inaba, Izumi, & Uesaka, 1977). The T-cell depletion was coupled to relapse in 
early reports but with the established protocol of in vivo ATG, the relapse risk has decreased 
(Busca & Aversa, 2017; Marmont et al., 1991). The finding that T-cell depletion not only 
abolished the GvHD, but also the GvL, established the theory that T-cells mediated both 
GvHD, but also a significant part of the GvL in human. The definition of GvL is however not 
stringent. If it is to be the effect of the graft against the leukemia, the GvL should not extend 
when the graft-failed, or monitoring with cytogenic – or molecular sampling gives the 
opportunity to use a DLI to prevent a fulminant relapse. To be stringent, GvL should be only 
the effect of the transplanted graft. Relapse incidence should instead measure the total quality 
of the care given at the center, including the protective effects of the DLIs that are given. This 
separation of GvL from relapse incidence does make the effects of the anti-cancer effect of 
the conditioning regimen clearer and it further allows for transparent evaluation of the graft-
versus-host prophylaxis and theGvHD. 
There is no recommended second line treatment after the first line of corticosteroids. The 
combination with etanercept and basiliximab in mostly severe cutaneous acute-GvHD is 
promising; with 75.4% CR but holds a two year survival of 54.7% and a relapse incidence of 
19%. These results should be compared to the studies of severe cutaneous acute-GvHD by 
photochemotherapy, where Wiesmann et al. had grade II-III of cutaneous acute-GvHD with a 
response of 92% and a 55% survival with 20% relapse (absolute numbers), and Furlong et al. 
had the majority grade III of cutaneous acute-GvHD with 57% response and 51% survival at 
129-1883 days. It is, however, difficult to compare these numbers, as it is at least fifteen years 
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between the study of etanercept and basiliximab and the studies of photochemotherapy, and 
the results of transplantation has improved world-wide due to improved protocols and 
supportive therapy.  
Photochemotherapy has a high potential to induce interstrand links when compared to other 
DNA crosslinking agents as Nitrogen Mustard, Mitomycin C and Platinum (Wilson & 
Seidman, 2010). This comparison underscores the biological effects of photochemotherapy. 
The photochemotherapy is described to decrease the antigen presenting cell load and the 
costimulatory capacity of the skin which are essential for the T-cell maturation and 
proliferation that causes GvHD. Photochemotherapy promotes apoptosis of cells in the skin, 
and after phagocytosis of apoptotic dendritic cells, the phagocytizing dendritic cell aquires 
the ability to induce antigen specific regulatory T-cells, to the antigen, that the apoptotic 
dendritic cell was presenting (Kushwah et al., 2009). Recently focus on the mediation of the 
effects of photochemotherapy have shifted to lower doses of topical photochemotherapy and 
bath-photochemotherapy where an induction of regulatory T-cells has been found both in 
animal and in human (Furuhashi et al., 2013; Kubo et al., 2017). Regulatory T-cells are 
missing in gastrointestinal biopsies from patients with intestinal GvHD after UVB (Rieger et 
al., 2006), and an experimental murine model of acute-GvHD of the gut has shown a curative 
effect of UVB coupled to the induction of regulatory T-cells in the gastrointestinal tract. The 
mechanism behind suberythemal ultraviolet light induced effects on experimental murine 
acute-GvHD after allogeneic bone-marrow-transplantation, (C57BL/6 to BALB/c), was 
studied in a routine TBI protocol without control group. The results showed an increased 
survival and a gastrointestinal acute-GvHD that resolved, associated with an increased 
infiltration of regulatory T-cells in the viscera. In addition, a decreased incidence of 
interstitial pneumonitis syndrome (IPS) was noted, together with an increase presence of 
regulatory (FoxP3+) cells in the lungs of the hosts (Hashimoto et al., 2016). An analogy 
would be that photochemotherapy mediate cure in the same way, by inducing regulatory T-
cells, which home to the gut. This would be intriguing since both bath-PUVA and 
photochemotherapy have longer lasting effects compared to UVB in psoriasis (Brazzelli et 
al., 2008; Stern, 2007). One mechanism behind this could be that photochemotherapy induces 
Vitamin D3 (Shuster et al., 1981), which stabilizes the inhibitory T-regulatory function and 
increases dendritic cell production of retinoic acid which in turn increases the gut homing of 
regulatory T-cells (Bakdash et al., 2015; Iwata et al., 2004; Kang et al., 2012; Sato et al., 
2013).  
There is a controversy of whether there is a predominant Th1 or a predominant Th17 pattern 
within the cutaneous acute-GvHD (Broady et al., 2010; Bruggen et al., 2014; Reinhardt et al., 
2014). It is not clear whether this is secondary to different modalities of conditioning 
regimens, with more RIC therapies in the Th17 studies, whether it depends on the laboratory 
methods used, or if it depends on the time-point for the skin biopsy compared to the onset of 
the cutaneous acute-GvHD, were the Th17 biopsies may have been later in the disease. 
Photochemotherapy, however, has been associated both with a downregulation of Th1 
cytokines in the skin (Olaniran et al., 1996), and a shift from the th17 towards the regulatory 
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T-cell population (Furuhashi et al., 2013), why this controversy over the cytokine profile fits 
well with photochemotherapy, regardless of the outcome. There are indications between an 
association between the skin and the gastrointestinal tract, indicated by clinical retrospective 
report (Martin et al., 1990) and from histopathology studies where concomittant cutaneous 
acute-GvHD has a slightly elevated specificity and sensitivity for GvHD confirmed by a 
biopsy from the upper gastrointestinal channel (Roy et al., 1991; Wu et al., 1998). In the 
experimental transplant model with TBI conditioning regimen, the regulatory T-cells induced 
by phototherapy (UVB) was found in the gut but also in the lung (Hashimoto et al., 2016). 
This suggests that photochemotherapy may have an effect on the adverse immunity in the 
lung too. In addition, the Vitamin D3 induced by photochemotherapy (Shuster et al., 1981), 
has been suggested to be deficient in lung disease (Beyhan-Sagmen et al., 2017; Maatta et al., 
2017). To conclude, when treating patients with cutaneous acute-GvHD, the efficacy of 
photochemotherapy is at the same level as other therapies. The relapse incidence or survival 
does seem to be in comparison to the latest antibody therapy of acute-GvHD. Systemic 
effects of photochemotherapy, beyond the indications of circulating regulatory cells, are not 
generally acknowledged. 
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3 THEORY AND AIM OF THE THESIS 
3.1 THE THEORY IN USE 
Treatment with photochemotherapy of the skin can be made without any effects on internal 
disease; i.e., without effects on pathological process in any organs beside the skin. 
Photochemotherapy is used to avoid a general immunosuppressive effect by steroids or other 
immunosuppressive pharmaceutic therapy. 
Cutaneous acute-GvHD is known as the most common manifestation of GvHD (Martin et al., 
1990). The clear important logic interpretation of a theory of a selective effect on cutaneous 
acute GvHD by photochemotherapy would be: when cutaneous acute-GvHD erupts, 
photochemotherapy is the “Holy Grail”, the treatment that may separate the systemic graft-
versus-leukemia from the graft-versus-host disease in the skin. 
The prevalence of a paradigm of a selective immunosuppressive effect on the skin by 
photochemotherapy was supported by the previous studies of photochemotherapy where no 
measurement on relapse or visceral disease was assessed (Atkinson, Weller, Ryman, & 
Biggs, 1986; Aubin et al., 1995; Furlong et al., 2002; Wiesmann et al., 1999). 
The current praxis is that photochemotherapy is used for acute-GvHD predominantly in the 
skin (Deeg, 2007). 
3.2 THE STRENGTH OF THIS THEORY:  
The theory of an effect selective to the skin is simple, “what you treat is what you see”. It 
focuses on the easily understandable view, that if you treat a disease in the skin, you should 
treat the skin. It relays on the tradition of that the photochemotherapy is used to treat diseases 
of the skin since ancient time. With a predominant perception that GvL is a systemic process 
and that GvL is most dominant in chronic GvHD or at least a chronic GvHD that follows an 
acute GvHD, photochemotherapy of the skin early after GvHD would not be an issue for the 
adoptive tumor immunity. 
3.3 THE WEAKNESS OF THIS THEORY: 
The theory does not consider the skin as the biggest organ in the body. It does not 
acknowledge the systemic effect which antigen provocation through the skin has been proven 
to have, evident by the effects of intradermal vaccinations (Bacille Calmette-Guérin by 
Mantoux technique). In addition, the theory of a selective effect on the skin is in conflict with 
animal studies where systemic suppressor cells were found (Kripke M.L. 1983; Wolf P. 
2006) Further, these studies pointed out that to suppress a delayed type hypersensitivity and 
induce cell that could be transferred to a syngeneic animal, you would have to treat 
unaffected skin, this is also in conflict with the theory as it is an acute-GvHD, predominantly 
in the skin that is the indication for treatment (Deeg, 2007). 
 
68 
3 THEORY AND AIM OF THE THESIS 
3.1 THE THEORY IN USE 
Treatment with photochemotherapy of the skin can be made without any effects on internal 
disease; i.e., without effects on pathological process in any organs beside the skin. 
Photochemotherapy is used to avoid a general immunosuppressive effect by steroids or other 
immunosuppressive pharmaceutic therapy. 
Cutaneous acute-GvHD is known as the most common manifestation of GvHD (Martin et al., 
1990). The clear important logic interpretation of a theory of a selective effect on cutaneous 
acute GvHD by photochemotherapy would be: when cutaneous acute-GvHD erupts, 
photochemotherapy is the “Holy Grail”, the treatment that may separate the systemic graft-
versus-leukemia from the graft-versus-host disease in the skin. 
The prevalence of a paradigm of a selective immunosuppressive effect on the skin by 
photochemotherapy was supported by the previous studies of photochemotherapy where no 
measurement on relapse or visceral disease was assessed (Atkinson, Weller, Ryman, & 
Biggs, 1986; Aubin et al., 1995; Furlong et al., 2002; Wiesmann et al., 1999). 
The current praxis is that photochemotherapy is used for acute-GvHD predominantly in the 
skin (Deeg, 2007). 
3.2 THE STRENGTH OF THIS THEORY:  
The theory of an effect selective to the skin is simple, “what you treat is what you see”. It 
focuses on the easily understandable view, that if you treat a disease in the skin, you should 
treat the skin. It relays on the tradition of that the photochemotherapy is used to treat diseases 
of the skin since ancient time. With a predominant perception that GvL is a systemic process 
and that GvL is most dominant in chronic GvHD or at least a chronic GvHD that follows an 
acute GvHD, photochemotherapy of the skin early after GvHD would not be an issue for the 
adoptive tumor immunity. 
3.3 THE WEAKNESS OF THIS THEORY: 
The theory does not consider the skin as the biggest organ in the body. It does not 
acknowledge the systemic effect which antigen provocation through the skin has been proven 
to have, evident by the effects of intradermal vaccinations (Bacille Calmette-Guérin by 
Mantoux technique). In addition, the theory of a selective effect on the skin is in conflict with 
animal studies where systemic suppressor cells were found (Kripke M.L. 1983; Wolf P. 
2006) Further, these studies pointed out that to suppress a delayed type hypersensitivity and 
induce cell that could be transferred to a syngeneic animal, you would have to treat 
unaffected skin, this is also in conflict with the theory as it is an acute-GvHD, predominantly 
in the skin that is the indication for treatment (Deeg, 2007). 
  69 
3.4 THE QUESTION 
The question to be elucidated was if the theory was true, did photochemotherapy not have 
any systemic effects after transplantation? Was photochemotherapy the “Holy Grail” of 
transplantation? Could photochemotherapy separate GvL from GvHD? These question is of 
high relevance for the field of transplantation as recurrence of disease are the most common 
cause of treatment failure, and GvHD is the second most common cause of death after 
transplantation, and cutaneous GvHD is an important predictor of GvHD treatment failure 
when concomitant visceral GvHD disease is percent (McDonald et al., 2017; D. Weisdorf et 
al., 1990). 
3.5 GENERAL AIM  
To test if the theory that the effect of photochemotherapy is confined to the skin could be 
falsified.  
3.5.1 Specific aims 
1. To evaluate the effect of photochemotherapy on acute-GvHD in relation to the stage of 
cutaneous acute-GvHD, the dose of photochemotherapy, and the previous therapies. 
The efficacy of photochemotherapy on disease beyond the skin would be tested on: 
 The GvHD of the liver and the gastrointestinal tract  
 The effect on pulmonary mortality 
2. To investigate the safety of photochemotherapy in cutaneous acute-GvHD with regards to 
GvL in relation to temporality between the onset of cutaneous acute-GvHD and start of 
photochemotherapy: 
 No effect would be seen according to theory? 
 An early start of treatment would be longer from chronic GvHD and safer? 
 An early start would abrogate a cell mediated response that started together with 
acute-GvHD? 
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4 METHOD 
4.1 FORMATION OF A COHORT 
The patients transplanted at Karolinska University Hospital Huddinge between 1980 – 2005 
who had signed written consent for prospective data collection (425/97) were assessed for 
eligibility by two researchers who screened the CAST-register, and by two researchers who 
screened the archives at the Dermatology department. The results were double checked with 
the records at Haematology and the prospective charts at CAST by one researcher and one 
physician, and one physician and one researcher reviewed the acute-GvHD diagnosis and the 
steroid resistancy (Le Blanc et al., 2008). A cohort of 116 transplants in 115 patients was 
presented in Firenze at the 34 th EBMT meeting 2008. The primary cohort data was reported 
to and retrieved from the CAST-database based by written consent to ethical permission 
425/97. The studies followed the declaration of Helsinki and were approved by the local 
ethical committee by ethical permission 425/97 and 2012/969-31/3, with addendum 
2014/1569-32. 
4.2 DESIGN OF DISEASE SPECIFIC FOLLOW-UP 
The ten year follow-up was organized by disease, and clinical uncertainties concerning the 
follow-up data was resolved after control with the patient records together with Omazic B., 
Ringdén O and Emtestam L. The following diseases were investigated in patients with 
cutaneous acute-GvHD. The studies were designed to falsify the theory of 
photochemotherapy as inducing effects isolated to the skin. 
Study I: Patients with GvHD of the liver and the gut (n=33), a flowchart of the study design 
is shown in Figure 1., Study I. 
 
Study II: Patients with acute-leukemia (n=47) assessed for effects on tumor immunity 
(GvL), the study design is shown in Figure 1., Study II.  
Study III: Patients with disease only in the skin (n=79), assessed for effects on the lung, the 
Figure 1., Study III., provides a flowchart of the study design. 
Study IV: Patients with chronic-leukemia with HLA-ID related donor, (n=22) assessed for 
effects tumor immunity (GvL). A reference group was formed with comprising patients 
(n=22), who had received T-cell depletion, either ex-vivo, or in-vivo (ATG). The study 
design for Study IV is shown in Figure 1., Study IV.  
The follow-up data was provided from the CAST-database (co/ Uhlin M. Remberger M. and 
Mattsson J). The reports were based on the STROBE protocol and ClincalTrials.gov was 
used for protocol registration for Study 2 and 3, identifier NCT02631993 and NCT03320928 
(NLM at the NIH).   
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4.3 TRANSPLANT CHARACTERISTICS 
The disease risk was stratified into high-risk and low-risk (Alyea et al., 2010; Ringden et al., 
1988). The donor and the recipient were matched for HLA-A, HLA-B, and HLA-DR.  The 
predominant conditioning regimens were based on cyclophosphamide together with 
myeloablative total-body-irradiation or myeloablative busulfan (Hassan, 1999; Ringden et al., 
1996). The majority of the unrelated donors received anti-thymocyte globulin (ATG) (Busca 
& Aversa, 2017; Ringden et al., 2000). The graft-versus-host prophylaxis was mainly based 
on methotrexate with cyclosporine; a minority of the patients had single therapy of either 
methotrexate or cyclosporine (Ringden et al., 1993; Storb et al., 1986). 
4.4 ACUTE CUTANEOUS GVHD OF THE SKIN 
The skin disease was stratified at the start of photochemotherapy, at the end of 
photochemotherapy and up-until fourteen days after photochemotherapy. The skin disease 
was diagnosed based on the clinical presentation together with a skin biopsy when possible 
and required. The skin diagnose was stratified by the total body surface area (TBSA) covered 
with rash according to Glucksberg et al. and the IBMTR severity index (Glucksberg et al., 
1974; Rowlings et al., 1997). 
4.5 TUMOR IMMUNITY 
Adoptive immunity with preserved anti-tumor immunity was considered present if the patient 
did not have relapse of malignant disease after photochemotherapy, or minimal residual 
hematological malignant disease (MRD) that demanded a donor-lymphocyte infusion (DLI) 
(Sairafi et al., 2010). Relapse or MRD were diagnosed and followed-up as mentioned in 
1.18.4, and was reported to the CAST database. Death or graft-failure, including 
retransplantation or booster not triggered by relapse or MRD (Remberger et al., 1998), was 
considered as a competing event. 
4.6 DISEASE OF THE LIVER, GUT, AND LUNG 
The disease of liver and gut was staged on the same time-points as cutaneous acute-GvHD. 
The lung disease was considered significant if the patient died from an infectious or non-
infectious cause with presumed pulmonary tissue involvement and comprised pneumonia, 
IPS with or without pulmonary infection, interstitial fibrosis and undefined respiratory 
insufficiency.  
4.7 PHOTOCHEMOTHERAPY 
The skin was photosensitized with 8-methoxysalen (0.4-0.8 mg/kg) orally two hours before 
irradiation with Long-wave UVA. Long-wave UVA (320-400 nm) was administered with the 
full-body UV1000 supine unit (Waldmann, Villingen-Schwenningen, Germany) with 26 
Waldmann F85 100-W fluorescence photochemotherapy lamps or Waldmann UV3003K 
half-body unit with 15 Waldamann F85 100-W photochemotherapy lamps. The total dose of 
photochemotherapy was measured as the total number of treatments, the dose J/cm2 per 
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treatment and the total accumulated dose J/cm2. The genital area of males was shielded 
during irradiation, and eye protection was used 24 hours after the oral administration of 8-
methoxysalen (Parrish J.A. 1974; Henseler T. 1981). 
4.8 ADDITIONAL GVHD TREATMENT 
Photochemotherapy was primarily started when the GvHD was steroid resistant after 
persistent GvHD after one week of prednisone (2mg/kg i.v.) or on the recurrency of a steroid 
taper, but was also started as single therapy, or concomittant with steroids. Methotrexate was 
given concomitantly with photochemotherapy as a part of the GvHD-prophylaxis protocol or 
as a GvHD treatment. Additional GvHD treatment was recorded when present. 
4.9 STATISTICS 
Descriptive statistics were used to describe the patient- and transplant characteristics. Non-
parametric statistics were used to compare confounding associations between groups.  
Cox-F-test was used to compare difference between groups, Cox-Proportional Hazards Ratio 
was used for multivariate analysis, Log-rank was used where no complete events were 
present in either group to base the cox-analysis on, and Kaplan-Meier was used to depict the 
groups and to estimate the cumulative survival (Cox D.R. 1964; Kaplan E.L. 1958). The 
events per variable was controlled to ensure the stability in the multivariate analysis (Peduzzi 
P. 1995). Statistica 64, 1985-2015, Dell Inc. (2015). Dell Statistica (data analysis software 
system), version 13. Software dell.com was used for the statistics. 
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5 THE RESULTS 
5.1 STUDY I. 
 
The majority of the patients, 94% (31/33), were transplanted for hematological malignancies, 
with a homogenous myeloablative conditioning regimen in 97% (32/33), which was based on 
TBI in the majority of the cases, 85% (16/28), and busulfan in 18% (5/28). All but one 
received cyclophosphamide, and one patient received fludara (RIC). The GvHD prophylaxis 
was mainly, 76% (25/33), methotrexate and cyclosporine, with six patients who had 
cyclosporine in monoprophylaxis and three patients who received T-cell depletion. There was 
no significant difference with regards to the characteristics of the patients, (n=33), in relation 
to skin disease stage (1-3), at start of photochemotherapy, which can be seen in table 1, 
Study I. The patients, had acute GvHD encompassing one of the visceral organs, liver or the 
GI in addition to the skin. Liver acute-GvHD was present in 69% (24/33) and GI acute-
GvHD was present in 56% (17/33). The patients with most cutanenous acute-GvHD, (stage 
3), had least involvement of disease in both the liver and the GI (0/11), compared to (4/11), 
(stage 2) and (4/10) for the patients with acute cutaneous-GvHD stage 1.  
The acute-GvHD was resistant to steroid treatment in (93%) when photochemotherapy 
started. The patients with the middle severity of acute-GvHD, (stage 2), had a slightly earlier 
onset of acute-GvHD and photochemotherapy after transplantation compared to the group 
with stage 1 and the group with stage 3 cutaneous acute-GvHD. The distribution of 
gastrointestinal tract acute-GvHD in relation to the severity of the cutaneous acute-GvHD can 
be seen in Figure 2a, Study I, and the distribution of liver acute-GvHD in relation to the 
cutaneous acute-GvHD can be seen in Figure 2b, Study I. The characteristics of the acute-
GvHD in relation to the skin disease stage (1-3) at start of photochemotherapy can be seen in 
detail in table 2, Study I.  
The photochemotherapy dose was higher in the patients that responded completely in their 
visceral disease, median 11 treatments (range 5-33), (p = 0.03), compared to 6 treatments, 
(range 1-26) in the patients who did not reach a CR in visceral acute-GvHD. The 
photochemotherapy in the CR group was given during median 25 days (range 10-94), 
(p=0.06), compared to median 19 days (range 4-48). The average dose was median 1.55 
(range 0.79 – 3.10), vs. 1.25 (range 0.57 – 2.33) and the accumulated dose was median 19.2 
J/cm2 (interquartile range 8 – 40; range 5.79 – 65.0), vs. 11 J/cm2 (range 4-46) in the patients 
who did not reach a response, (p = 0.05). The majority of the patients with a complete 
response in the visceral and the cutaneous acute-GvHD, 81% (13/16), could have a steroid 
taper (>50% decrease in (mg/kg bodyweight), compared to 29% (5/17) of the patients who 
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did not respond completely in their visceral disease (p = 0.003). The degree of cutaneous 
acute-GvHD at start of treatment did not correlate to a steroid taper.   
The complete response to cutaneous acute-GvHD in the skin and viscera was 39% (13/33) 
and the responding patients, (CR + partial response (PR)), was 64%. No response could be 
seen in 24% (8/33) and 12% (4/33), progressed (CIBMTR classification). Beside the GvHD-
prophylaxis, methotrexate was added in two patients who did respond completely, and anti-
thymoglobulin or mycophenolate was added to two patients who did not respond. The liver 
and/or gastrointestinal response in relation to the cutaneous acute-GvHD stage can be seen in 
Figure 2b & 2d, Study I. 
The patients who responded in their visceral acute-GvHD, did respond after a lower dose of 
photochemotherapy (p = 0.04), (n=15), and a lower dose of UVA per treatment, (p = 0.04), 
(n=16) when they had a less severe cutaneous acute-GvHD, Figure 3. a & b, Study I, and a 
slightly lower accumulated UVA dose (n=13), Figure 3c. Study I. The chance of a response 
in the viscera tended to be higher in the patients with cutaneous acute-GvHD stage 1, (p = 
0.07) at day 28, day 56 and day 100, (Figure 4a) Study I. The cumulative proportion of GI 
acute-GvHD with anti-thymocyte treatment as GvHD-prophylaxis during the conditioning 
(in-vivo T-cell depletion), and liver acute-GvHD, are plotted against the CR in GI acute-
GvHD in patients without ATG during the conditioning, p = 0.01)., Figure 4b. Study I.  
The patients who received total body irradiation in the myeloablative conditioning regimen 
responded completely in their visceral disease after photochemotherapy at a higher rate 
(16/28) compared to none of the five patients with myeloablation by busulfan (0/5), (p = 
0.045). A post-hoc analysis of pediatric patients is limited to two cases among the patients 
with TBI and photochemotherapy with (100%) 2/2 cutaneous response, 100% (1/1) in liver 
acute GvHD and 100% (1/1) in GI acute GvHD. The adult & pediatric experience show a 
cumulative response among the surviving at 67% (p = 0.034, Log-Rank-Test), when 
comparing the patients with TBI to those without, and a better 10-year relapse free survival 
and overall survival (32%), (p= 0.039) and (32%), (p = 0.039), respectively. 
The 6-months overall survival was 64%. To start photochemotherapy at cutaneous acute-
GvHD stage 1, showed a trend to a better 10-year survival compared to the a more severe 
cuteanous acute-GvHD (p = 0.096), Figure 5a. Study I. The group with CR in visceral 
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5.2 STUDY II. 
 
The outcome of the group with the time-point for start of photochemotherapy within the first 
week after the onset of cutaneous acute-GvHD and the outcome of the group with 
photochemohterapy start after the first week of cutaneous acute-GvHD were comparable, 
since the demographics and transplantation characteristics of the patients at the start of 
photochemotherapy with regards to the time-to-photochemotherapy after the onset of acute 
GvHD did not differ, table 1. Study II.; The GvHD prophylaxis and treatments, did differ, 
with regards to corticosteroid treatment table 2. Study II.; The GvHD organ disease stage at 
the start of photochemotherapy and characteristics of photochemotherapy, was similar at the 
time-point when photochemotherapy was initiated table 3. Study II. The time from 
transplantation to cutaneous acute-GvHD and the time from transplantation to 
photochemotherapy was lower in the patients who started photochemotherapy early, the 
median time for start in the early group was day 1 (range 0-7) compared to day 19.5 (8-52), in 
the group with a more delayed treatment, table 4. Study II. 
 
The GvHD answered similarly to treatment, regardless if the photochemotherapy was started 
early, where 77% (10/13) had CR; 85% (11/13) responded (CR+PR), and there was one non-
responder, and one patient progressed, compared to start of photochemotherapy after the first 
week of cutaneous acute-GvHD, when the CR was 76% (26/34), and 80% responded 
(CR+PR), whereas three did not respond, and three progressed. 
The GvL was predicted by a start after the first week of cutaneous acute-GvHD (p = 0.0018). 
This more delayed start of photochemotherapy was at day median 19.5 (range 8-52), and the 
relapse risk was predicted by an early start of photochemotherapy and a lower stage of 
cutaneous acute-GvHD at start of photochemotherapy (p = 0.004) in the cox-proportional 
hazards ratio (HR) univariate and multivariate analysis with 5,000 days follow-up after 
transplantation, for details see table 5. Study II. The Kaplan-Meier Curves of the cumulative 
proportion of GvL coupled to photochemotherapy, and the cumulative proportion of 
leukemia relapse risk can be seen in Figure 2 and Figure 3 a& b, Study II. 
The survival with preserved GvL and the leukemia-free-survival were both predicted by a 
delayed start of photochemotherapy, but not the overall 5,000 day survival, table 6, Study II. 
The Kaplan-Meier curves of the cumulative proportion of survival with preserved GvL, the 
cumulative proportion of leukemia-free survival and the cumulative proportion of survival are 
shown in Figure 4 a,b & c. Study II. 
The time-to photochemotherapy after the onset of cutaneous GvHD counted in days, a 
continous variable, was a predictor for GvL (p = 0.017), in a model which was as valid as 
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when time-to photochemotherapy was handled a binary variable, with early vs. delayed start 
(start during the first week vs. after the first week of onset of cutaneous acute-GvHD), (p = 
0.003). The multivariate analysis of the time-to photochemotherapy as a binary and a 
continuous predictor for GvL can be seen in table 7. Study II. 
5.3 STUDY III. 
 
The majority of the patients, 77% (61/79), received myeloablation by total body irradiation 
(TBI), – fractionated irradiation was given (3 Gy/day) on four consecutive days to an 
accumulated dose of 12 grays, and non-fractionated TBI was given as a one day single dose 
of 10 Gy. Myeloablative busulfan (16 mg/kg), was given in 20% (16/79). In one patient 
reduced conditioning was given with reduced busulfan (8mg/kg)  and in one patient reduced 
TBI (2 Gy) was given, both in combination with Fludara. 
Bone-marrow-grafts were given to the majority of the patients 86% (68/79), whereas 
peripheral blood stem cells were given to 14% (11/79). Anti-thymocyte globulin was given in 
39% (31/79). The graft-versus-host prophylaxis in 91% (72/79) was based on methotrexate, 
with or without cyclosporine, T-cell depleted bone marrows were given to four patients, and 
three patients received cyclosporine without methotrexate, two of them together with 
prednisolone. 
At start of photochemotherapy, the acute-GvHD was confined to the skin where acute-GvHD 
covered was stage 1 and covered up to 25% of the TBSA in 43% (34/79); stage 2 in 41% 
(32/79) and stage 3 where the acute-cutaneous GvHD covered more than 50% of the TBSA 
in 16% (13/79) of the patients. The majority of the patients 75% (59/79) had CR of their 
cutaneous acute-GvHD, and the response, (CR+PR), was 93% (73/79). The CR in cutaneous 
acute-GvHD after 30 days or less of photochemotherapy was 54% (41/76) and the CR in 
acute GvHD was 49% (37/76); (MD data for exact finish day of photochemotherapy (n=3)); 
The CR after 56 days or less was 68% (53/78) for skin and 62% (48/78) in total; (MD for 
exact day of finish of photochemotherpy (n=1); and the CR after 100 days or less was 75% 
(59/79) and 68% (54/79) in total (all patients with onset of visceral disease during 
photochemotherapy were counted as a non-responders). The cutaneous acute-GvHD severity, 
acute-GvHD prophylaxis and treatment characteristics are shown in table 2. Study III. In a 
non-parametric fisher-exact test, a stage 3 cutaneous acute-GvHD at start of 
photochemotherapy was associated with a CR in cutaneous acute-GvHD; (p = 0.016); but not 
with CR in acute-GvHD, (p = 0.10), as gastrointestinal disease started in one patient with 
cutaneous acute-GvHD stage 1, and three patients with cutaneous acute-GvHD stage 2, of 
whom one in addition had onset of liver acute-GvHD, whereas one patient with cutaneous 
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acute-GvHD stage 3 had onset of GI acute-GvHD during the course of photochemotherapy. 
Methotrexate was associated with an increase in creatinine, ALAT and an increased risk for 
chronic GvHD. Pulmonary mortality was 19% (15/79) and occurred at median day 217 
(range 63-1297). Mortality after relapse occurred at median day 499 (range 97-3396), 
(p<0.05). The pulmonary mortality associated with opportunistic infections came at median 
day 122 (range 104 – 217) and pulmonary mortality of non-opportunistic cause came at 
median 390 days (358 – 892]. A more severe cutaneous acute-GvHD of the skin was the 
multivariate predictor for pulmonary mortality; HR 4.49, 95% CI [2.05 – 9.82], (p < 0.001). 
The pulmonary mortality was present in the group treated with TBI, methotrexate and 
hematological malignancy. In the subgroup treated with TBI (n=61), CR of cutaneous acute 
GvHD after photochemotherapy protected from pulmonary mortality in a univariate analysis 
HR 0.34 [0.12 – 0.96], (p = 0.04), but a more severe cutaneous acute-GvHD remained the 
multivariate predictor HR 4.06 [1.91 – 8.64]; (p < 0.001). The results of the univariate- and 
multivariate analysis are presented in table 3, Study III. 
The cutaneous acute-GvHD severity (The TBSA covered by rash), protected from relapse, as 
it was the inverse predictor for relapse risk; HR 0.51 95% CI [0.26 – 0.99], (p > 0.05); Figure 
3. Study III. The cumulative proportion of survival and relapse free survival are shown in 
Figure 4&5, Study III. 
5.4 STUDY IV. 
 
The majority received myeloablative TBI (10 Gy), (7/8) in the group that started 
photochemotherapy within a week after onset of cutaneous acute-GvHD, whereas in the 
group who delayed the start of photochemotherapy after the first week, (10/14) received 10 
Gy and one patient received 7.5 Gy. One patient in the group with early treatment start and 
three in the group with delayed treatment start received busulfan. All patients received 
cyclophosphamide. The demographics and clinical characteristics of the patients at start of 
photochemotherapy grouped by the time to photochemotherapy after onset of acute-GvHD 
did not differ between the groups in the study group (n=22), or in the T-cell depleted 
reference group (n=22), table 1A & 2A Study IV.  
The graft-versus-host prophylaxis was mainly Cyclosporine and Methotrexate; one in the 
group which started photochemotherapy more than one week after the onset of cutaneous 
acute-GvHD received single methotrexate prophylaxis and one received cyclosporine. There 
was one female to male donor-recipient relationship in the early group. The group who 
started photochemotherapy within one week had only one steroid resistant acute-GvHD (1/8), 
whereas the majority (13/14) in the delayed group were steroid resistant, (p < 0.001). 
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The dose of photochemotherapy (the number of treatments), the dose per treatment (J/cm2) 
and the accumulated dose (J/cm2), were similar regardless of photochemotherapy started 
within a week from onset of acute-GvHD or whether it started after one week of unrelenting 
cutaneous acute-GvHD, table 2A, Study IV. 
The cutaneous acute-GvHD responded completely (CR) in the majority, 88% (7/8), in the 
group who started photochemotherapy within a week, at median 3.5 days (range 0 – 7), from 
the onset of cutaneous acute-GvHD. Two patients who resolved the cutaneous acute-GvHD 
had onset of liver acute-GvHD and in one patient the cutaneous acute-GvHD was persistent 
and in addition a GI acute-GvHD had developed. In the group where photochemotherapy was 
started after one week of cutaneous acute-GvHD at median 21.5 days (range 8 – 40) after the 
onset of cutaneous acute-GvHD, the GvHD responded in 93% (13/14), (CR+PR) and 
responded completely (CR) in 86%, 12/14. The remaining patient progressed into a fulminant 
stage IV cutaneous acute-GvHD. There was an onset of liver acute-GvHD in two patients 
who had resolved their GvHD in the group who started photochemotherapy after the first 
week of cutaneous acute-GvHD. In the ex-vivo or in-vivo T-cell depleted reference group, 
who received unrelated transplants, there was a higher degree of antigen-mismatched 
transplants and the patients who started photochemotherapy after the first week of cutaneous 
acute-GvHD, at median 15.5 days (range 8 – 43 ), had a lower degree of CR of cutaneous 
acute-GvHD. The doses of photochemotherapy was comparable, with a tendency to a lower 
dose per treatment in the T-cell depleted patients who had received photochemotherapy 
within a week of onset of cutaneous acute-GvHD, at median 3.5 days ( range 0 – 6) (p = 
0.06), table 2B. Study IV. 
The group who started photochemotherapy after the first week of cutaneous acute-GvHD 
(n=14) had a stronger GvL effect compared to the patients who started photochemotherapy 
within a week from the onset of cutaneous acute-GvHD (p = 0.038 cox F-test), Figure 3A 
Study IV.  
The relapse incidence did not differ with regard to the time-to treatment between onset of 
acute-cutaneous GvHD and start of photochemotherapy in the depleted control cohort, (p = 
0.49 log rank), Figure 3B, Study IV 
Three patients in the non-depleted group had received anti-thymocyteglobulin after 
transplantion, the GvL remained strong in these patients, who all were in the HLA-identical 
group, who started treatment at more than one week after the onset of cutaneous acute-
GvHD, (n=11) vs. (n=8), (p = 0.022), Figure 3C. Study IV.  
The ten-year survival estimate was 50% (Kaplan-Meier) when photochemotherapy started 
more than one week after the onset of cutaneous acute-GvHD, this trended to be superior to 
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start of photochemotherapy during first week of cutaneous acute-GvHD (p = 0.09) overall 
survival, (p = 0.07) leukemia free survival, Figure 4A and 4B, Study IV. Likewise, the 
survival and the leukemia free survival was slightly better in the patients that received ex-
vivo or in-vivo T-cell depletion concomitant with the transplantation and started 
photochemotherapy after the first week of cutaneous acute GvHD, Figure 7A and 7B, Study 
IV. 
Chronic GvHD had a cumulative incidence of 80%, in the patients who were transplanted 
without a depletion procdure, i.e. (5/8) and (10/14), whereas the incidence of chronic GvHD 
in the group with T-cell depletion during the transplantation was 70%. In a landmark 
analysis, where the median day of chronic GvHD onset was used (day 171), GvL was not 
improved by acute- and chronic-GvHD Figure 5A., and Figure 6A & 6B, Study IV. In the 
T-cell depleted transplantations, which includes the unrelated transplantations where anti-
thymocyteglobulin was used, chronic-GvHD did not improve the GvL, (Figure 5B. and 6C-
D), Study IV. 
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6 THE DISCUSSION OF THE THESIS 
 
The key result of Study I is the association between total body irradiation (TBI) in the 
conditioning regimen and the complete response (CR) in visceral acute-GvHD by 
photochemotherapy in patients after clinical transplantation. This was further supported in a 
post-hoc analysis, where TBI predicts both visceral GvHD response and long-term overall 
and relapse free survival. An explorative analysis indicates that ATG may inhibit the effects 
in the viscerawhich suggest that the T-cells depleted by ATG is present in the mediation of 
the systemic effect after photochemotherapy. The results support a biological gradient where 
photochemotherapy has a stronger effect when a lower degree of the skin is affected by 
cutaneous acute-GvHD. The response of the acute-GvHD is well within the range of 
established systemic immunotherapies used as secondary therapies against acute-GvHD 
(chapter 1.14). The results suggest a systemic effect of photochemotherapy after 
transplantation. 
 
The relation between total-body-irradiation (TBI) and complete response (CR) in visceral 
disease after photochemotherapy is an intriguing result. The mechanism of an increased 
response when the DNA-damaging photochemotherapy follows after TBI is suggested to be 
secondary to the additional DNA-damage (Study I), but there may be a synergistic effect. At 
30-days after TBI DNA double strand lesions remain, which theoretically would increase the 
density of underwound DNA in the recipient cells in the skin. The remaining double stranded 
lesions not only add to the load of the total-DNA-damage, in addition, in the repair process 
the supercoiling of the DNA-molecule is changed into an under wound state which makes 
DNA repair possible (Cech & Pardue, 1977; Corless & Gilbert, 2017), and furanocoumarins, 
like psoralen, are more likely to bind to the DNA in the underwound state (Cech & Pardue, 
1977).  This repair process may hypothetically still be ongoing to repair lesions that are not 
yet cured thirty days after TBI when photochemotherapy started. Thus there may be a 
synergy between ionizing irradiation and furanocoumarin-based therapies like 
photochemotherapy. During the peer-review process of Study I, Hashimoto et al. submitted 
and published a paper on the induction of regulatory T-cells by UVB which heal 
gastrointestinal acute-GvHD caused by transplantation after a conditioning regimen by TBI 
in an experimental murine model. This finding has been discussed in chapter 2. In 
comparison to Study I, Hashimoto et al. has no other conditioning regimen, and one cannot 
say that the results presented are dependent on the effects remaining after the TBI; however 
the mechanistic presentation of the induction of regulatory T-cells after phototherapy and the 
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effects on acute-GvHD in the liver, lung, and gut is substantial (Chapter 2). An increased 
level of regulatory (FoxP3+) T-cells is well documented in human after Bath-
photochemotherapy (Furuhashi et al., 2013; Kubo et al., 2017). In clinical transplantation, a 
dysregulation of the conventional T-cell ratio (CD8+) and the regulatory T-cell ratio is 
described in the small- and the large intestine (Rieger et al., 2006). In Study III we find that a 
CR of cutaneous acute-GvHD after photochemotherapy possibly is associated with a 
decreased incidence of pulmonary mortality in patients who has received a conditioning 
regimen with myeloablative total-body-irradiation (TBI). The first time an increased response 
on acute-GvHD after phototherapy (UVB or UVA+psoralen) has been associated to TBI is in 
the Study I comparison with chemotherapy (busulfan) myeloablative conditioning. The 
results from Study I, i.e. that photochemotherapy of the skin after a conditioning with TBI 
may resolve acute systemic GvHD, e.g. liver and gut, is strengthened by the findings in 
Study III, where a decreased pulmonary mortality is present after CR in the cutaneous acute 
GvHD after treatment with photochemoterhapy. These results from a study of patients with 
cutaneous acute-GvHD and liver and/or gut acute GvHD (Study I), and from a study where 
CR in cutaneous acute-GvHD by photochemotherapy decreases pulmonary mortality in 
patients treated by TBI (Study III), support a theory where photochemotherapy has effects 
on acute-GvHD during the first 100 days after a conditioning with myeloablative TBI. 
 
Study III suggests that cutaneous acute-GvHD predisposes for pulmonary mortality. The 
perspective in this Study Is from the clinical presence of a well-defined skin disease towards 
the cause of death secondary to a decreased organ function in the lung. It has long been well-
known that a patient after allogeneic stem cell transplantation that is in need of mechanical 
ventilation has a fatal prognosis (Fukuda et al., 2003). In addition it is well known the lung 
function during the first year after transplantation is decreased, especially in patients with 
acute GvHD. But from the opposite point of view, from a histopathological perspective the 
association between cutaneous acute-GvHD and a particular pulmonary histopathology seems 
unlikely. In two reports of the early histopathological pattern after cutaneous disease five out 
of five patients are placed into different groups secondary to the histopathological pattern 
found in lung biopsies, e.g. cicatrial bronchiolitis obliterans (BO), bronchiolitis obliterans 
organizing pneumonia (BOOP), acute lung injury (ALI) and bronchiolitis obliterans 
syndrome (BO), (Xu et al., 2013; Yousem, 1995). An evaluation from the histopathological 
perspective thus only may reveal cutaneous acute-GvHD as a part of the causes of each 
different pattern of pulmonary acute-GvHD. However, in all different patterns, there is 
however an infiltration of lymphocytes typical for acute GvHD (Xu et al., 2013; Yousem, 
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1995). The histopathology and the search for causes of pulmonary mortality in human gets 
even more diverse when infections are taken into account, which were thoroughly excluded 
from these retrospective histopathological studies discussed here and in Chapter 1.6.13. 
However, infections are common in the lung of the patients with immunosuppression 
secondary to acute-GvHD and acute-GvHD high dose steroid treatment. A comparison to 
smoking, which damages the lung, reveals from the histopathological viewpoint different 
disease patterns which each may lead to death, e.g. chronic obstructive pulmonary disease 
(COPD) with severe pulmonary emphysema or with an acute excacerbation by infectious 
ethiology and as a final point different lung cancers. From each of these predictors, it is in a 
minor set of patients not as easy to identify the tissue damage of smoking as the common 
cause. However, if the outcome is set to “death in pulmonary mortality”, in the same way as 
it was set secondary to evaluate the tissue damage the patient were exposed to associated with 
cutaneous acute-GvHD in Study III, a biological gradient (a dose-response correlation) may 
be evident also in a limited group of patients. The results of Study III are straightforward, the 
association between cutaneous acute-GvHD severity and pulmonary mortality is highly 
significant, highly prevalent and death comes early. Furthermore, in temporality, the higher 
danger of an opportunistic infection is evident, as viral and fungoid causes of death comes 
significantly earlier than non-opportunistic causes of death. This emphasizes that severe 
cutaneous acute-GvHD ought to be regarded as a systemic disease with effects on internal 
organs. There is a high risk of concomitant systemic involvement, were the histopathological 
pattern of the disease in the tissue in specific can be diverse. The patients that are transplanted 
are a population of patients with severe disease, often with a long an compromising previous 
medical history, and a long period of immunosuppression, where the lung is an organ that is 
at high risk for viral, bacterial and mucosal infections in the time period before 
transplantation and as well as after transplantation e.g. before, during and after cutaneous 
acute-GvHD. Therefore it is suggested that when searching for the organ failure underlying 
different causes of death with systemic impact after transplantation, infections in the organ 
and what seems like non-infectious causes shall include a stage where infectious and non-
infections histopathological disease patterns, or presumed primary tissue injury, shall be 
pooled together. The infiltration of allogeneic cytotoxic T-cells in the organ with specificity 
for the patient tissue, and not for infections, both destroys the organ, but also may allow 
infections to thrive in the damaged tissue. In addition these patients often are on heavy 
pharmaceutic systemic immunosuppression, and are for a long time not fully reconstituted in 
their immune defence which further increases the risk for fatal mold and viral disease. To 
conclude, this study reveals a high incidence of pulmonary mortality coupled to cutaneous 
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acute-GvHD, which cannot be revealed if the cause of each infection or each histopathology 
is analyzed separately. The possible protection against pulmonary death if a complete 
response in cutaneous acute-GvHD can be reached by photochemotherapy must be 
investigated further. Furthermore, the Study III suggests a biological gradient of systemic 
damage evoked by cutaneous acute-GvHD. The Chapter 1.6 introduces the systemic 
inflammation of acute-GvHD, and the upregulation of Elafin that is a marker of cutaneous 
acute-GvHD, but also of the acute-respiratory-distress syndrome (Chapter 1.6.9). Finally, 
Chapter 1.7.4 presents the correlation between severe acute-GvHD and lung disease that 
Beschorner et al. described (Beschorner et al., 1978)). It was known that acute-GvHD grade 
II or more was associated with severe lung disease after transplantation, but that the 
pulmonary mortality was directly depended on the TBSA covered by cutaneous acute-GvHD 
was not acknowledged. The pattern of presumed lung tissue injury after cutaneous acute-
GvHD indicated by Study III can can be specific to the lung or general to the internal organs 
i.e. either is this systemic damage of the activated T-cells in cutaneous acute GvHD more 
fatal specifically to in the lung, which is a site of brisk immune responses (Strieter, Belperio, 
& Keane, 2002), or either does the cutaneous acute-GvHD exaggerate acute-GvHD 
generally, including the lung. T-cell driven mediation of early pulmonary damage is 
supported by the finding showing that T-cell depletion reduces early severe complications in 
the lungs (Ho et al., 2001).The impact of the increased dose-response effect of 
photochemotherapy related to a lower degree of cutaneous acute-GvHD found in Study I, 
subsequently must be regarded as confounded by the concomitant increased  impact on the 
internal organs by the severe cutaneous acute-GvHD. The increase in the systemic 
inflammation may increase the risk for increased organ involvement of acute-GvHD 
systemically, which includes the visceral acute-GvHD, and thus may make it more difficult to 
bring the visceral disease into CR. This impose that the visceral disease may be harder to treat 
by the systemic inflammatory response secondary to an increased stage of cutaneous acute-
GvHD and thus need an increased dose of photochemotherapy. The results of Study I stands 
however well out when comparing to other secondary therapies of mainly steroid resistant 
acute-GvHD (Martin et al., 2012), and with the indications of the effects  of cutaneous acute-
GvHD on the lung indicated in Study III, as well as the well-known increased risk for 
treatment failure for visceral GvHD with concomitant cutaneous acute-GvHD (McDonald et 
al., 2017; D. Weisdorf et al., 1990), the results indicate that photochemotherapy induces a 
systemic immunosuppressive effect with effects on the disease in internal organs,  
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The good of the treatment of cutaneous acute-GvHD by photochemotherapy is  underscored 
by both Study I and Study III, especially after a conditioning regimen of TBI. In general, all 
studies and times encounter, there was a good complete response of cutaneous acute-GvHD 
treated by photochemotherapy 83%  (range 75%-88%), a response which is in similarity to 
the previous clinical experience of photochemotherapy of cutaneous acute-GvHD (Atkinson 
et al., 1986; Aubin et al., 1995; Eppinger, Ehninger, Steinert, Niethammer, & Dopfer, 1990; 
Furlong et al., 2002; Wiesmann et al., 1999);(Chapter 1.16.1). The pooled results of 
extracorporeal photochemotherapy from eight studies of pediatric acute GvHD has a pediatric 
cutaneous response of median 80% (50 – 100%), liver median 67% (range 0 – 100%) and gut 
median 74% (range 57% - 83%) (Alfred et al., 2017). In Study I, the cumulative adult- and 
pediatrics results in the TBI group were a CR of 67% on acute-GvHD, and although the 
number of patients in Study I was limited, the results in the two pediatric cases it was 100%, 
why the results for photochemotherapy after TBI may be in the same magnitude as 
extracorporeal photochemotherapy.  
 
The Study II is a reports of a  regulation of the GvL reaction by timing of a secondary GvHD 
therapy. The GvL seem to be regulated by the time between photochemotherapy and 
cutaneous acute-GvHD, in general, but predominantly in the patients without T-cell depletion 
and/or ATG. This effect is present both in patients with Acute- and chronic leukemia (Study 
II & IV). The window when the tumor immunity (GvL) is elicited is what we know, not 
defined for any other secondary GvHD therapy. The weak GvL secondary to 
photochemotherapy during the first week after the onset of cutaneous acute-GvHD as well as 
the identification of photochemotherapy as a continuous predictor of GvL suggests that 
photochemotherapy touches important mechanisms within the elicitation of GvL. The time 
window for the mechanism behind GvL in early animal studies has been identified to be 
during the first week (Chapter 1.8). This was not perceived as a problem when 
photochemotherapy was given with the goal to minimize the immunosuppression to the skin, 
in benefit of the patient and the GvL more than ten years ago. The mechanism behind a 
possible decrease in the GvL during the first week after the onset of cutanenous acute-GvHD  
can be caused by the decreased   antigen-presentation of the skin, and the change in 
costimulation caused by photochemotherapy. If we allow ourselves to see GvHD and GvL as 
adaptive immunity against different antigens on different cell surfaces, GvL could be 
understood by the same mechanisms that govern GvHD. The first step is tissue damage (we 
know that the conditioning regimen is important to eradicate cancer (Chapter 1.9, but we do 
also know that the tissue damage by the conditioning regimen upregulates the antigen 
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presentation on common tissues, and more so on tissues of hematopoietic lineage, and the 
leukemia is of hematopoietic lineage). The second step is T-cell activation and proliferation, 
during this stage a crosspresentation and oligoclonal expansion also may take place. It is 
during this stage photochemotherapy was administered when it was administered early. 
Photochemotherapy does downregulate adhesion markers, which makes it more difficult for 
the T-cells to enter the skin, further photochemotherapy decreases the antigen presentation of 
the skin as a tissue and does downregulate the costimulatory capacity of the antigen 
presenting cells of the skin (Chapter 1.17). These mechanisms is suggested to limit the 
expansion of activated T-cells towards effector T-cells against the antigen presented. 
Hypothethically, this early photochemotherapy may also decrease the possibility of the 
adaptive immunity against the cancer, the tumor immunity. 
A later start of photochemotherapy was given to a majority of patients with steroid-resistant 
disease. These patients have at a higher degree been exposed to the systemic inflammatory 
stage of GvHD (Chapter 1.6.4). It cannot be ruled out that the steroid treatment may have had 
an effect on the GvL, but the identification of photochemotherapy as a continuous predictor 
indicates that the role of corticosteroids may be limited. There may be GvL without GvHD in 
patients that are not treated with steroids (Ringden et al., 2000), why the effect of steroids on 
GvL in general and in this study may not be critical, why the time-dependent-difference with 
regard to photochemotherapy ought to be considered as the main result. This said it cannot be 
clearly delineated if the photochemotherapy weakens the GvL if given early, or strengthens 
the GvL if it is given late. Besides the more developed systemic immune response with a later 
start of photochemotherapy, which now may have launched the GvL safely in analogy with 
what we know about the mechanisms in GvHD, we have the reports of the induction of 
regulatory T-cells by photochemoterapy (Chapter 1.17). These regulatory T-cells are reported 
to have a cytotoxic effect against cells of hematopoietic lineage (Chapter 1.17.7), and the 
leukemia is of hematopoietic linage. Hypothetically, the effects of photochemotherapy may 
both be an inhibition of adaptive immunity if given early, but also a healer of GvHD by 
restoration of the regulatory T-cell balance in the tissue, and possibly an eradicator of tumor-
cells by the induction of regulatory-T-cells.  
 
The incidence of chronic GvHD were evaluated in Study IV, and was found to be (80%), and 
(70%) in patients with ATG. In general ATG seem to inhibit the effects of 
photochemotherapy, suggested by the possibly decreased effect on gastrointestinal acute-
GvHD in patients treated by photochemotherapy after total-body-irradiation (Study I), but 
also by the indications of a preserved GvL in patients where photochemotherapy was given 
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The incidence of chronic GvHD were evaluated in Study IV, and was found to be (80%), and 
(70%) in patients with ATG. In general ATG seem to inhibit the effects of 
photochemotherapy, suggested by the possibly decreased effect on gastrointestinal acute-
GvHD in patients treated by photochemotherapy after total-body-irradiation (Study I), but 
also by the indications of a preserved GvL in patients where photochemotherapy was given 
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during the first week after onset of acute GvHD, in patients given ATG or T-cell depletion 
and/or ATG during the conditioning regimen (Study II or Study IV). The use of ATG 
diminished the dendritic cells and the T-cells in the graft, as an in-vivo T-cell depletion. This 
suggests that it is cell mediated immunity modulated in photochemotherapy, and is 
compatible with the hypothesis of regulatory-T-cells as the population that is mediating the 
effect of decreased tissue damage in the lung and the gut after photochemotherapy of 
cutaneous acute-GvHD. 
 
There is a controversy over the cytokine pattern in cutaneous acute-GvHD, where recent 
findings of a Th17 (Bruggen et al., 2014; Reinhardt et al., 2014) pattern is questioning 
persistent reports of a Th1 cytokine pattern (Broady et al., 2010; Remberger et al., 2003); 
(Chapter 1.6.5). Whether this controversy is secondary to novel conditioning regimens in the 
Th17 studies, sampling later on in the time course of GvHD, where also more steroids have 
been used, or whether it is secondary to differences in laboratory methods is not clear. 
However, photochemotherapy is reported to both decrease the Th1 and the Th17 pattern in 
cutaneous disease, why this controversial may be of lesser importance to the clinical utility of 
photochemotherapy on cutaneous acute-GvHD. 
 
The internal validity of the results has been safe-guarded by the use of register data from the 
established database at CAST which is an internationally highly regarded transplant center. In 
addition, objective outcomes were used e.g. complete response (CR) in acute GvHD and 
time-points for start of treatment, as well as survival and relapse. The major weaknesses of 
these studies are the limited number of patients which increases the risk of a statistical error, 
and the retrospective nature which induces a risk for selection bias regarding the basis for the 
clinical decision on when and on what clinical signs photochemotherapy were to be started. 
The single center setting do reduce the impact of this bias as the longitudinal presence of a 
stable cadre of attending physicians were present during the time-interval of the study. The 
relative strength of the studies is that they comprise highly homogenous treatment regimens 
of photochemotherapy and highly homogenous transplant protocols with the overwhelming 
majority of patients myeloablative conditioning regimens (cyclophosphamide and 
myeloablation with TBI or busulfan) and graft-versus-host prophylaxis  (cyclosporine and/or 
methotrexate) with addition of anti-thymocyte globulin in the unrelated transplants. 
 
The external validity regarding the efficacy of photochemotherapy is limited to acute GvHD 
within which photochemotherapy most possible has a variable effect depending on the type 
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of previous treatment, the type of conditioning regimen, regarding which antibodies that may 
have been used during the conditioning regimen and as previous GvHD therapy, and what 
cell populations they deplete and for long, e.g. are the cell populations that takes part in the 
mechanism secondary to photochemotherapy still present or have they been depleted? 
Photochemotherapy after ATG seem to have less systemic effect as shown in Study I-IV. It 
is not guaranteed that the same effects can be seen in GvhD after transfusion or after liver 
transplantation.. However, with the findings of the stronger effect after TBI and the 
temporality of photochemotherapy after transplantation, the present research indicate that 
photochemotherapy has effects on disease in internal organs  after transplantation. Based on 
the present research I recommend that to optimize GvL photochemotherapy should be 
withheld the first week of onset of cutaneous acute-GvHD, but if ATG has been used 
treatment may start earlier if the need is urgent. The present research is however made on a 
transplant protocol that is in relatively close proximity to the myeloablative protocol of 
Thomas E.D. which on the otherhand has been close to an established international standard 
within allogeneic transplantation of acute-leukemia’s for over forty years. Patients who 
received donor-lymphocyte infusions or booster doses of T-cells were not eligible and the use 
of donor-lymphocyte infusions were considered as a loss of the graft-versus-leukemia effect 
from the adoptive immunity transplanted. This strict study design limits the validity of the 
studies of photochemotherapy to treatment after a myeloablative conditioning, after a 
predominantly HLA-matched transplantation  before DLI. Haploidentical transplantation 
with posttransplantation cyclophosphamide which may have an effect on the T-regulatory 
compartment early after transplantation (Chapter 1.12.2), has not been studied. There is a 
need for additional studies of the effects of photochemotherapy after DLI, where GvL has 
been reported to be elicited before GvHD (Chapter 1.12.7). The majority of the studies on 
secondary therapies against GvHD are retrospective, and the transparency of the tumor 
immunity of the Study I-IV is of good standard. The present research is done on the 
immunity adopted from the original graft both with regards to GvHD and GvL, which 
increases the reproducibility of the results. 
 
To conclude, Study I & III suggest that photochemotherapy of cutaneous acute-GvHD has 
beneficiary effects on the acute-GvHD of the GI and that it may decrease the risk for 
pulmonary mortality after transplantation, to which cutaneous acute-GvHD is identified as a 
risk factor. Study II & IV support two issues, first, that the first week of initial development 
of cutaneous acute-GvHD is critical for GvL, second, that photochemotherapy has systemic 
effects after transplantation. Thus, the theory of an effect of photochemotherapy confined to 
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the skin is suggested to be replaced by a theory where photochemotherapy has systemic 
effects after myeloablative allogeneic stem cell transplantation. The time-point for the clinical 
decision to use photochemotherapy of the skin may improve the disease of the gut, the lung, 
and the long-term cancer free survival. By comparing the four separate studies of this thesis, I 
suggest that the optimal time point for start of photochemotherapy in patients with 
hematological malignancy is at least after the first week of cutaneous acute GvHD. 
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7 FUTURE PERSPECTIVES 
7.1 TRANSPARANT REPORT OF GVL 
When it comes to the use of donor-lymphocyte- infusion (DLI), to hinder relapse and treat 
MRD in allogeneic transplantation, term “window of opportunity” has been established. 
However, when it comes to studies of secondary therapy, the term of relapse incidence is 
mostly undefined and it is not outspoken whether or not the use of DLI determines a loss of 
the GvL that the patient adopted from the primary transplantation. If the DLI succeds and the 
relapsing cells are eradicated, it is not clear that it is counted as a loss of GvL which is 
possibly induced by the therapies in place when the MRD became significant in the blood of 
the patient, or previous by previous therapies. Thus the modulation of the transplanted 
adoptive immunity by pharmacuetic therapies used to treat acute-GvHD may be 
underreported. The elaboration of a more transparent separation of GvL and relapse incidence 
defined as in the present thesis may improve the quality of the reports of clinical trials of 
GvHD therapies.  
7.2 THE TIMING OF PHOTOCHEMOTHERAPY 
The timing of photochemotherapy in relation to the onset of cutaneous acute-GvHD with 
regard to the effects on tumor immunity can be precised further. In the experimental murine 
studies, the GvL increased until day 6 (Chapter 1.8). In the present study, the lower limit of 
the group with optimal GvL is from day eight but the median day is during the third week 
after onset of cutaneous acute-GvHD. With regard to the detrimental effects on pulmonary 
disease correlated to cutaneous acute-GvHD, a closure of this time-gap with the hope of a 
better effect on GvHD could deliver an advantage for the patient. Prospective research 
coupled to photochemotherapy could also increase the knowledge of cutaneous acute-GvHD, 
with regards to the Th1 and the Th17 profile. The research also would give an opportunity to 
learn more of the regulatory cell population in regards to the optimal induction dose by 
photochemotherapy, as well as the effects within different tissues and with regard to tumor 
immunity. Foremost prospective randomized controlled research of photochemotherapy 
treatment of cutaneous acute-GvHD is needed for its promising effects on gastrointestinal- 
and lung GvHD which are great threats against the cure of leukemia. Importantly, a possible 
attenuation of the adverse effects of irradiation injury of the lung by photochemotherapy 
would be of great benefit to mankind as an established therapy to prevent from respiratory 
failure secondary to the acute-irradiation-syndrome is missing today. 
7.3 THE COMBINATION OF IONIZING IRRADIATION AND 
PHOTOCHEMOTHERAPY 
 
The effect of the combination of ionizing irradiation and ultraviolet light type holds promises 
of a new field of DNA modulation with secondary effects on immunology and cancer 
therapies. The combination may further have advantages within disinfection of surfaces and 
cutaneous infections as well as for systemic immunosuppression. The known risk for cancer 
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in patients with higher doses ionizing irradiation followed by photochemotherapy, where the 
lowest reported case is the patient who had four years of superficial X-ray therapy between 
1942-46 and developed squamous cell carcinoma in 1982 after a treatment of 51 J/cm2 during 
1.5 years (Torinuki W. 1988), sets the limit for exposure below an accumulated does of 50 
J/cm2.  The median response dose associated to visceral complete response in Study I. was 
19.2 J/cm2, but 50 J/cm2 was in the fourth quadrant in the patient group with most severe 
cutaneous acute-GvHD. The vast majority in the present studies responded to lower doses, 
and the dynamics of the regulatory cell population in psoriatic patients suggest that the 
appropriate effect can be reached well before an accumulated dose of 50 J/cm2 (Kubo R. 
2017). If a combined apparatus for ionizing irradiation and ultraviolet light type A is further 
developed, it can be used both extra corporeally and directly towards the skin and tumors. It 
is not known to what levels the ionizing irradiation may be minimized to provide and 
additive- or synergistic effect to UVB or photochemotherapy, but since DNA-damage which 
is sub-lethal to the cell is repaired at a high speed, there is a need to provide the ionizing 
irradiation and the ultraviolet light if possible as a part of the same procedure to minimize the 
adverse effect of each source of irradiation. The DNA-damage in living cells are dependent 
on the dose of ionizing irradiation (Banath, Fushiki, & Olive, 1998). DNA repair processes 
are present 7.5 at mSv (Nguyen et al., 2015), which is a dose that may be present during 
computer tomography, why therapeutic effects for severe disease may be within reach using 
the doses that diagnostic imaging use today. In addition, to the plausible induction of 
regulatory T-cells of a combined therapy, the field holds promise to give novel knowledge of 
the coupling between DNA-damage, DNA-repair and the link between DNA-damage and 
immunosuppression. A dysregulation of regulatory T-cells has been suggested in psoriasis, 
multiple sclerosis, necrotizing enterocolitis and myasthenia gravis (Danikowski, Jayaraman, 
& Prabhakar, 2017; Dingle et al., 2013). Estimated from the response of photochemotherapy 
on acute-GvHD a limited combined dose to treat severe diseases may provide competitive 
effects compared to the present therapies. A primary goal will be to evaluate the effect in 
animal models to see if regulatory T-cells can be induced by a combined therapy and to see if 
these regulatory T-cells in turn may cure acute-GvHD, and possible also provide a granzyme 
dependent anti-tumor effect within the hematologic cell population.  
 
7.4 STRESSED DNA, A NOVEL TARGET  
 
A fourth field of future research is the possibility to increase the stress of DNA by modest 
levels of ionizing irradiation or ultraviolet light, to easier insert molecules in underwound 
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DNA secondary to DNA damage. The DNA can be human or prokaryote or viral, and besides 
to attach molecules to the DNA, the stress of the DNA-damage can also make it easier to 
target the process of DNA-repair. Furthermore, a combined therapy can have unexplored 
antibacterial properties secondary to DNA-damage. Novel ways of eradicating bacteria are 
needed with regard to the increased resistance against the therapies of today. The process of 
DNA repair is different between eukaryotes and prokaryotes, why this could lead to the 
invention of new antibiotics.   
7.5 PHARMACEUTIC MODULATION OF ACUTE-GVHD TO ERADICATE 
CANCER 
 
There is a growing awareness that acute-GvHD may crucial to succeed to cure the high-risk 
cancers which may be the mainstay indication for future myeloablative transplantation when 
pharmacuetic- and cellular immunetherapies e.g. tyrosinase kinase -inhibitors or chimeric 
antigen receptor (T-CAR) therapies, have failed or does not match with the patient diagnosis 
(Chapter 1.1 & 1.18). I propose that the importance of acute-GvHD will continue to grow in 
importance, and with that will come the need of a detailed knowledge on how GvHD 
therapies will regulate the associated anti-tumor immunity that is the key to patient survival. 
In the post-transplantresearch we can rely on the knowledge from the development of graft-
versus-host prophylaxis, (Chapter 1.4 and Chapter 1.12.1 & 1.12.2), we do not know upfront, 
what effects a certain therapy will have on a certain type of GvL, against a certain type of 
cancer, with a certain type of GvHD. We can only continue to measure, continue to do our 
physical assessment, sample our biomarkers to improve the information upon which we make 
our clinical decision making and continue to assess the clinical outcome. Thus, future studies 
on the regulatory effect on GvL of acute-GvHD therapies with regard to the timing after the 
onset of acute-GvHD, with regard to the systemic biomarker pattern,  the changing cell 
populations during the different phases of acute-GvHD and secondary to the impact of the 
previous GvHD-prophylaxis and GvHD-therapy as well as the underlying malignancy are 
warranted. 
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